###begin article-title 0
###xml 126 130 <span type="species:ncbi:10090">mice</span>
Peroxisome proliferator-activated receptor beta activation promotes myonuclear accretion in skeletal muscle of adult and aged mice
###end article-title 0
###begin p 1
We reported recently that peroxisome proliferator-activated receptor beta (PPARbeta) activation promotes a calcineurin-dependent exercise-like remodelling characterised by increased numbers of oxidative fibres and capillaries. As physical exercise also induces myonuclear accretion, we investigated whether PPARbeta activation alters myonuclear density. Transgenic muscle-specific PPARbeta over-expression induced 14% increase of myonuclear density. Pharmacological PPARbeta activation promoted rapid and massive myonuclear accretion (20% increase after 48 h), which is dependent upon calcineurin/nuclear factor of activated T cells signalling pathway. In vivo bromodeoxyuridine labelling and proliferating cell nuclear antigen immunodetection revealed that PPARbeta activation did not promote cell proliferation, suggesting that the PPARbeta-promoted myonuclear accretion involves fusion of pre-existing muscle precursor cells to myofibres rather than cell division. Finally, we showed that in skeletal muscle, ageing led to a down-regulation of PPARbeta accompanied by decrease of both oxidative fibre number and myonuclear density. PPARbeta pharmacological activation counteracts, at least in part, the ageing-driven muscle remodelling.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 210 211 210 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 534 536 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
Adult skeletal muscle displays a remarkable capacity for regeneration and adaptation. Skeletal myofibres represent the largest cells in the body. They are syncitial, post-mitotic and terminally differentiated [6, 13, 37]. Muscle fibres are unable to proliferate but contain a pool of muscle precursor cells (MPCs), commonly called "satellite cells", which reside between the basal lamina and the sarcolemma [19]. The term of muscle precursor cells is used in this report due to the heterogeneity within the satellite cell population [40].
###end p 4
###begin p 5
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">44</xref>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
MPCs play crucial roles in muscle physiology, particularly in muscle repair and regeneration. In response to stress-induced myofibre damages, reparation results from the fusion of MPCs with damaged but viable myofibres [25, 27, 28] and regeneration from the fusion of several MPCs within the basal lamina of the destroyed fibres for de novo myofibre formation [25, 31, 33, 44]. MPCs proliferation is a preliminary and obligatory step of these processes [26].
###end p 5
###begin p 6
###xml 244 245 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 476 478 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 913 915 913 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
MPCs are also involved in adaptive response of skeletal muscle to acute and chronic changes in intensity or type of physical activity, such as muscle functional overload, treadmill running, chronic motor nerve stimulation or voluntary running [2, 16, 30, 32]. In these particular conditions, MPCs proliferation is required for modifications of myonuclear density and myofibre hypertrophy but does not seem to be necessary for fibre twitch from faster to slower phenotype [16, 29]. However, myonuclear accretion is an early event of the adaptive response to aerobic training which is characterised by a transition from glycolytic to oxidative fibres. Furthermore, Tseng et al. showed that slow fibres always had small volume/myonucleus regarding to fibre diameter and that fast/oxidative fibres with high succinate dehydrogenase (SDH) activity appeared to have lower volume/myonucleus than fast/glycolytic fibres [39]. These differences in nuclear domain size between fibre types were proposed to be related to the greater amount of proteins required for oxidative metabolism, including those implicated in mitochondrial structure and functions.
###end p 6
###begin p 7
###xml 308 310 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 594 595 594 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 720 721 720 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 947 948 947 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 1121 1123 1121 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">45</xref>
###xml 635 639 <span type="species:ncbi:10090">mice</span>
###xml 732 737 <span type="species:ncbi:10090">mouse</span>
Finally, the role of MPCs in age-related muscle atrophy is poorly documented, and conflicting observations have been reported. It seems that ageing does not affect the ability of MPCs to respond to various challenges even if there might exist a delay in the proliferative responses of MPCs from aged muscle [12]. Brack et al. reported that in large fast muscle fibres, the decrease of myonuclei per muscle unit preceded muscle atrophy. Authors proposed that the age-related decrease in myofibre size may actually be a compensatory response to an inadequate capacity for myonuclear replacement [4]. Bruusgaard et al. reported that aged mice display a reduction of muscle size as well as a reduction in myonuclear number [5]. In aged mouse muscles, authors have visualised many fragmented nuclei suggesting increased apoptosis and have proposed that reduction of myonuclei in old muscle could result in a reduction of regenerative capacity of MPCs [5]. This hypothesis is in contrast with previous observations made in muscle inactivity experiments, in which fibre size reduction precedes the decrease in myonuclei number [45].
###end p 7
###begin p 8
###xml 208 210 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 212 214 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 368 370 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 372 374 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 463 465 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 626 628 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 630 632 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 634 636 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 638 640 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">41</xref>
###xml 832 834 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1032 1034 1017 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 141 146 <span type="species:ncbi:10090">mouse</span>
###xml 618 624 <span type="species:ncbi:9606">humans</span>
We previously described the effect of peroxisome proliferator-activated receptor (PPARbeta) over-expression or pharmacological activation in mouse tibialis anterior (TLA), a fast/oxidative-glycolytic muscle [10, 17]. In both models, we reported an impressive muscle remodelling characterised by 37% hyperplasia and an increase in oxidative fibre and capillary number [10, 18]. In PPARbeta agonist-treated animals, this remodelling takes place within only 2 days [10]. Because of the observed oxidative and angiogenic remodelling as well as the improvement of metabolic profiles of PPARbeta agonist-treated animals and humans [15, 21, 36, 41], it was proposed that activation of the PPARbeta pathway mimics, at least partially, the adaptive response of muscle to aerobic training. Muscle hyperplasia is indicative of MPC activation [14]. Furthermore, we have actually reported an increase of Myf5 and MyoD1 proteins immediately after pharmacological PPARbeta activation using GW0742, also suggesting the possible activation of MPCs [10].
###end p 8
###begin p 9
###xml 755 757 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 899 901 884 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
###xml 414 418 <span type="species:ncbi:10090">mice</span>
###xml 1051 1056 <span type="species:ncbi:10090">mouse</span>
As physical exercise and ageing are two physiological situations affecting myonuclear densities, we asked how PPARbeta over-expression or pharmacological activation affects myonuclear number in the TLA muscle from young and aged mice. Furthermore, we investigated whether or not MPC proliferation was required. We report here a new striking phenotype for both PPARbeta over-expressing and PPARbeta agonist-treated mice. In both cases, the number of nuclei per unit of fibre length is significantly increased. This augmentation of myonuclear density follows the same kinetic as the previously described muscle oxidative and angiogenic remodelling induced by PPARbeta pharmacological activation, starting at day 1 and being completed at day 2 of treatment [10]. Interestingly, myonuclear accretion does not require cell proliferation. As previously described for other PPARbeta-dependent remodelling [10], the increase in myonuclear density is prevented by inhibition of the calcineurin pathway. Finally, we show that PPARbeta is down-regulated in aged mouse muscles and that pharmacological PPARbeta activation, using GW0742, restores in large part the age-related loss of myonuclei.
###end p 9
###begin title 10
Materials and methods
###end title 10
###begin title 11
Animals
###end title 11
###begin p 12
Animals were maintained in a 12/12 h lighting cycle and received food (UAR, France) and water ad libitum. All experimental procedures were conducted according to French legislation. Ten-week-old male C57BL6J (Janvier, France) and 10 weeks and 19 month-old male B6D2 (maintained in our animal facility) were used in the various experiments. We always used four animals per condition to obtain statistical values. Animals were killed after the indicated times by cervical dislocation, and tibialis anterior muscles were harvested immediately after killing.
###end p 12
###begin p 13
###xml 105 107 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 289 291 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 124 128 <span type="species:ncbi:10090">mice</span>
###xml 214 218 <span type="species:ncbi:10090">mice</span>
###xml 252 257 <span type="species:ncbi:9606">human</span>
###xml 567 571 <span type="species:ncbi:10090">mice</span>
Animals over-expressing PPARbeta specifically in skeletal muscle were generated as previously described [18]. Briefly, B6D2 mice harbouring a loxP-stop-loxP-PPARbeta-hygromycine construction were crossed with B6D2 mice expressing Cre recombinase under human skeletal actin (HSA) promoter [20]. All animals were maintained hemizygous for their transgene. Presence of the transgenes was verified by polymerase chain reaction (PCR) analyses of tail DNA (REDExtract-N-Amp Tissue PCR Kit, Sigma). Animals harbouring the two transgenes were used as PPARbeta-overexpressing mice, while animals harbouring the HSA-Cre transgene only were used as control.
###end p 13
###begin title 14
Injections
###end title 14
###begin p 15
###xml 39 41 36 38 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">38</xref>
###xml 176 179 173 176 <sc xmlns:xlink="http://www.w3.org/1999/xlink">a.m</sc>
###xml 232 235 229 232 <sc xmlns:xlink="http://www.w3.org/1999/xlink">a.m</sc>
GW0742, a PPARbeta-specific activator [38], was dissolved in Dulbecco's modified Eagle's medium/dimethyl sulphoxide (DMSO) 6% (Gibco) and injected subcutaneously once a day (9 a.m.) at 1 mg/kg. Control animals received vehicle at 9 a.m..
###end p 15
###begin p 16
###xml 64 67 64 67 <sc xmlns:xlink="http://www.w3.org/1999/xlink">a.m</sc>
###xml 75 78 75 78 <sc xmlns:xlink="http://www.w3.org/1999/xlink">p.m</sc>
###xml 200 203 200 203 <sc xmlns:xlink="http://www.w3.org/1999/xlink">p.m</sc>
###xml 260 263 260 263 <sc xmlns:xlink="http://www.w3.org/1999/xlink">a.m</sc>
###xml 268 271 268 271 <sc xmlns:xlink="http://www.w3.org/1999/xlink">p.m</sc>
###xml 279 282 279 282 <sc xmlns:xlink="http://www.w3.org/1999/xlink">p.m</sc>
###xml 303 306 303 306 <sc xmlns:xlink="http://www.w3.org/1999/xlink">a.m</sc>
###xml 314 317 314 317 <sc xmlns:xlink="http://www.w3.org/1999/xlink">p.m</sc>
###xml 336 339 336 339 <sc xmlns:xlink="http://www.w3.org/1999/xlink">p.m</sc>
Cyclosporine A (Sigma) treatments were performed twice a day (9 a.m. and 6 p.m.) by subcutaneous injections at 25 mg/kg in DMSO. In these experiments, GW0742 was injected subcutaneously once a day (2 p.m.) at 1 mg/kg. Injections of vehicle were performed at 9 a.m., 2 p.m. and 6 p.m. (Control group), 9 a.m. and 6 p.m. (GW group) and 2 p.m. (CsA group).
###end p 16
###begin p 17
###xml 53 56 53 56 <sc xmlns:xlink="http://www.w3.org/1999/xlink">a.m</sc>
###xml 204 207 204 207 <sc xmlns:xlink="http://www.w3.org/1999/xlink">p.m</sc>
###xml 264 267 264 267 <sc xmlns:xlink="http://www.w3.org/1999/xlink">a.m</sc>
###xml 275 278 275 278 <sc xmlns:xlink="http://www.w3.org/1999/xlink">p.m</sc>
BrdU (Sigma) treatments were performed once a day (9 a.m.) by intra-peritoneal injections of the compound at 100 mg/kg in 0.9% NaCl. In these experiments, GW0742 was injected subcutaneously once a day (2 p.m.) at 1 mg/kg. Injections of vehicle were performed at 9 a.m. and 2 p.m. in control groups.
###end p 17
###begin title 18
Immunofluorescence analysis
###end title 18
###begin p 19
###xml 136 140 <span type="species:ncbi:10090">mice</span>
###xml 349 354 <span type="species:ncbi:10090">Mouse</span>
###xml 418 422 <span type="species:ncbi:9925">goat</span>
###xml 428 433 <span type="species:ncbi:10090">mouse</span>
Tibialis anterior (TLA) muscles and duodenum were harvested and frozen in tissue embedding medium (VWR International) immediately after mice were killed. Ten-micrometre cryosections were performed from the middle part of muscle or from duodenum, placed on poly-lysine coated slides (VWR International) and processed for immunofluorescence analyses. Mouse monoclonal NFATc1 (7A6, sc-7294, Santa Cruz Biotechnology) and goat anti-mouse fluorescein conjugate antibodies were both used at 1:200 dilution. For BrdU immunofluorescence, cryosections were fixed on slide according manufacturer's protocol and then incubated 45 min with an anti-BrdU antibody (Anti-Bromodeoxyuridine-Fluorescein, Roche). Finally, slides were mounted with Vectashield containing DAPI (H-1200, Vector laboratories, Burlingame, CA, USA). Slides were viewed under an epifluorescence microscope connected to a digital camera with the Spot software (Universal Imaging).
###end p 19
###begin title 20
Histological and immunohistochemical analysis
###end title 20
###begin p 21
###xml 332 337 <span type="species:ncbi:10090">mouse</span>
TLA muscles and duodenum were harvested, fixed in 4% paraformaldehyde (PFA) overnight, dehydrated and then embedded in paraffin. Paraffin sections (5 mum) were used for either BrdU or PCNA antigen detection using M.O.M. Kit (PK-2200, Vector Laboratories). BrdU (11170376001, Roche), PCNA (PC10, Sc-56, Santa Cruz Biotechnology) and mouse monoclonal antibodies were used in a 1:50 and 1:100 dilution, respectively. DAB (SK-4100, Vector Laboratories) served as a substrate. Nuclei were counterstained with haematoxylin. Slides were viewed under an epifluorescence microscope connected to a digital camera with the Spot software (Universal Imaging).
###end p 21
###begin title 22
Single-fibre isolation
###end title 22
###begin p 23
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 237 238 237 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 239 240 239 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">v</italic>
Single fibres were isolated. Both fibre length and myonuclear number were assessed as described by Brack et al. [4]. Briefly, TLA muscles were fixed in 4% PFA during 2 days at room temperature. Muscles were then treated 2 h in 40% NaOH (w/v) and agitated vigorously for 10 min. Released fibres were washed in phosphate-buffered saline (PBS; pH 7.4) and stored at 4degreesC in PBS 0.05% azide.
###end p 23
###begin title 24
Myonuclear density analysis
###end title 24
###begin p 25
After DAPI staining, images of 40 single isolated fibres per animal (four animals per group) were captured using a Z-stacking procedure on a Zeiss Apotome (x10 objective), then Z-projected using the open source ImageJ software (Wayne Rasband, National institutes for Health). Fibre diameters were measured at six locations over at least 500 mum length of the fibre, and all nuclei were counted using Olympus DP-Soft software. Values obtained were averaged to obtain mean value per fibre. Any damaged areas of the fibres were not analysed.
###end p 25
###begin title 26
Sodium dodecyl sulfate polyacrylamide gel electrophoresis and Western blot
###end title 26
###begin p 27
###xml 27 31 <span type="species:ncbi:10090">mice</span>
###xml 499 505 <span type="species:ncbi:9986">rabbit</span>
###xml 581 587 <span type="species:ncbi:9986">rabbit</span>
###xml 674 680 <span type="species:ncbi:9986">rabbit</span>
###xml 767 773 <span type="species:ncbi:9986">rabbit</span>
###xml 845 850 <span type="species:ncbi:10090">mouse</span>
###xml 922 927 <span type="species:ncbi:10090">mouse</span>
###xml 1000 1006 <span type="species:ncbi:9986">rabbit</span>
###xml 1035 1040 <span type="species:ncbi:10090">mouse</span>
Total TLA lysates from the mice treated with GW0742 or vehicle alone (DMSO) were prepared, electrophoresed and blotted on polyvinylidene difluoride membrane. Subcellular fractionation of TLA muscles was performed using the Qproteometrade mark Cell Compartment Kit (Quiagen) according to manufacturer's instructions. The following antibodies were used at the indicated dilutions for immunodetection: Pan A calcineurin (AB1695, Chemicon International) 1:1,000, polyclonal anti P85 (PI3K subunit) from rabbit (06-496, Upstate, Lake Placid, NY, USA) 1:1,000, polyclonal anti CREB from rabbit (kind gift of Dr. M. Montminy, San Diego, USA) 1:2,000, polyclonal anti Rho GDIa from rabbit (A-20, sc-360, Santa Cruz Biotechnology) 1:500, polyclonal anti acetyl-histone 3 from rabbit (06-599, Upstate, Lake Placid, NY,USA) 1:1,000, monoclonal NFATc1 from mouse (7A6, sc-7294, Santa Cruz Biotechnology) 1:200, monoclonal NFATc3 from mouse (F-1, sc-8405, Santa Cruz Biotechnology) 1:200, peroxidase-coupled anti-rabbit and peroxidase-coupled anti-mouse secondary antibodies (Vector Laboratories) 1:5,000.
###end p 27
###begin title 28
Quantitative reverse transcription PCR
###end title 28
###begin p 29
###xml 397 462 396 458 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">PPAR&#946;: 5&#8242;-AGATGGTGGCAGAGCTATGACC-3&#8242;; 5&#8242;-TCCTCCTGTGGCTGTTCC-3&#8242;.</p>
###xml 397 462 396 458 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">PPAR&#946;: 5&#8242;-AGATGGTGGCAGAGCTATGACC-3&#8242;; 5&#8242;-TCCTCCTGTGGCTGTTCC-3&#8242;.</p></list-item>
###xml 462 527 458 523 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31">Catalase: 5&#8242;-GGATCCTGACATGGTCTGGG-3&#8242;; 5&#8242;-TGGAGAGACTCGGGACGAAG-3&#8242;.</p>
###xml 462 527 458 523 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="31">Catalase: 5&#8242;-GGATCCTGACATGGTCTGGG-3&#8242;; 5&#8242;-TGGAGAGACTCGGGACGAAG-3&#8242;.</p></list-item>
###xml 527 592 523 588 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32">PDK4: 5&#8242;-GCATTTCTACTCGGATGCTCAATG-3&#8242;; 5&#8242;-CCAATGTGGCTTGGGTTTCC-3&#8242;.</p>
###xml 527 592 523 588 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32">PDK4: 5&#8242;-GCATTTCTACTCGGATGCTCAATG-3&#8242;; 5&#8242;-CCAATGTGGCTTGGGTTTCC-3&#8242;.</p></list-item>
###xml 592 656 588 652 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33">36B4: 5&#8242;-TCCAGGCTTTGGGCATCA-3&#8242;; 5&#8242;-CTTTATCAGCTGCACATCACTCAGA-3&#8242;.</p>
###xml 592 656 588 652 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33">36B4: 5&#8242;-TCCAGGCTTTGGGCATCA-3&#8242;; 5&#8242;-CTTTATCAGCTGCACATCACTCAGA-3&#8242;.</p></list-item>
###xml 397 656 396 652 <list xmlns:xlink="http://www.w3.org/1999/xlink" list-type="bullet"><list-item><p textid="30">PPAR&#946;: 5&#8242;-AGATGGTGGCAGAGCTATGACC-3&#8242;; 5&#8242;-TCCTCCTGTGGCTGTTCC-3&#8242;.</p></list-item><list-item><p textid="31">Catalase: 5&#8242;-GGATCCTGACATGGTCTGGG-3&#8242;; 5&#8242;-TGGAGAGACTCGGGACGAAG-3&#8242;.</p></list-item><list-item><p textid="32">PDK4: 5&#8242;-GCATTTCTACTCGGATGCTCAATG-3&#8242;; 5&#8242;-CCAATGTGGCTTGGGTTTCC-3&#8242;.</p></list-item><list-item><p textid="33">36B4: 5&#8242;-TCCAGGCTTTGGGCATCA-3&#8242;; 5&#8242;-CTTTATCAGCTGCACATCACTCAGA-3&#8242;.</p></list-item></list>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
Reverse transcription was performed using 0.2 mug of total RNA from muscle of 10 week-old and 19 month-old C57Bl6 mice (five animals per group), a Core kit (RT-RTCK-03, Eurogentec) according to manufacturer's instruction and a mix of random primers (9 mers) and oligodT. qPCR was performed on SDS7900HT (Applied Biosystem) using Mesagreen qPCR kit for SYBR (Eurogentec) and the following primers: PPARbeta: 5'-AGATGGTGGCAGAGCTATGACC-3'; 5'-TCCTCCTGTGGCTGTTCC-3'.Catalase: 5'-GGATCCTGACATGGTCTGGG-3'; 5'-TGGAGAGACTCGGGACGAAG-3'.PDK4: 5'-GCATTTCTACTCGGATGCTCAATG-3'; 5'-CCAATGTGGCTTGGGTTTCC-3'.36B4: 5'-TCCAGGCTTTGGGCATCA-3'; 5'-CTTTATCAGCTGCACATCACTCAGA-3'.
###end p 29
###begin p 30
PPARbeta: 5'-AGATGGTGGCAGAGCTATGACC-3'; 5'-TCCTCCTGTGGCTGTTCC-3'.
###end p 30
###begin p 31
Catalase: 5'-GGATCCTGACATGGTCTGGG-3'; 5'-TGGAGAGACTCGGGACGAAG-3'.
###end p 31
###begin p 32
PDK4: 5'-GCATTTCTACTCGGATGCTCAATG-3'; 5'-CCAATGTGGCTTGGGTTTCC-3'.
###end p 32
###begin p 33
36B4: 5'-TCCAGGCTTTGGGCATCA-3'; 5'-CTTTATCAGCTGCACATCACTCAGA-3'.
###end p 33
###begin p 34
Data were all normalised using 36B4 as housekeeping gene.
###end p 34
###begin title 35
Statistical analysis
###end title 35
###begin p 36
###xml 441 442 441 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 716 717 714 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
The effect of the duration of treatment was performed by a one-way analysis of variance (ANOVA) test. Two-way ANOVA tests were performed for comparisons between groups (age and treatment; age and transgenicity). When significant changes were observed in ANOVA tests, Fisher's protected least significant difference post hoc test was applied to locate the source of significant differences. When two groups were compared, we used a Student's t test. Analyses were performed with Stat'View Abacus Concept version 5. Hierarchical ascendant classifications were performed for the determination of fibre groups according to nuclei/mm of fibre length. Results are presented as means +/- SD with significance accepted when p < 0.05.
###end p 36
###begin title 37
Results
###end title 37
###begin title 38
PPARbeta pathway activation promotes an increase in myonuclear density in TLA muscle
###end title 38
###begin p 39
###xml 322 323 316 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 486 487 475 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 534 535 521 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 579 580 563 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 720 721 704 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 810 811 794 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 865 866 849 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 892 893 876 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1037 1038 1018 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1066 1067 1047 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1129 1130 1110 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1178 1184 1159 1165 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1269 1270 1247 1248 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1372 1374 1350 1352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 1401 1403 1376 1378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tg</italic>
###xml 1507 1508 1482 1483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1563 1564 1538 1539 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1699 1700 1671 1672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1811 1813 1783 1785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 1840 1842 1809 1811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tg</italic>
###xml 2127 2131 2096 2100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mean</italic>
###xml 2157 2161 2126 2130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">s.d.</italic>
###xml 2189 2191 2158 2160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 2218 2220 2184 2186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tg</italic>
###xml 1184 2226 1165 2192 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40">Muscle-specific PPAR&#946; over-expression promotes an increase of myonuclear density. <bold>a</bold> Representative isolated DAPI-stained fibres harvested from tibialis anterior of 10-week-old control (<italic>Ct</italic>) and PPAR&#946; transgenic (<italic>Tg</italic>) B6D2 mice. Global myonuclear density is indicated as myonuclei number per millimetre of fibre length (<italic>n</italic>&#8201;=&#8201;160, four animals per group, 40 fibres per animal). <bold>b</bold> Distribution of myofibres population in TLA from control and PPAR&#946; overexpressing mice. Myonuclei in isolated DAPI-stained fibres (<italic>n</italic>&#8201;=&#8201;160, four animals per group, 40 fibres per animal) harvested from tibialis anterior of 10-week-old control (<italic>Ct</italic>) and PPAR&#946; transgenic (<italic>Tg</italic>) B6D2F1 mice were quantified and pooled using ascendant hierarchical classification in three groups of fibres containing (1) less than 85 nuclei, (2) from 85 to 100 nuclei and (3) more than 100 nuclei/mm of fibre length. Percentage of each group, mean number of nuclei in each group (<italic>Mean</italic>) and standard deviation (<italic>s.d.</italic>) are reported for control (<italic>Ct</italic>) and PPAR&#946; transgenic (<italic>Tg</italic>) mice</p>
###xml 1184 2226 1165 2192 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="40">Muscle-specific PPAR&#946; over-expression promotes an increase of myonuclear density. <bold>a</bold> Representative isolated DAPI-stained fibres harvested from tibialis anterior of 10-week-old control (<italic>Ct</italic>) and PPAR&#946; transgenic (<italic>Tg</italic>) B6D2 mice. Global myonuclear density is indicated as myonuclei number per millimetre of fibre length (<italic>n</italic>&#8201;=&#8201;160, four animals per group, 40 fibres per animal). <bold>b</bold> Distribution of myofibres population in TLA from control and PPAR&#946; overexpressing mice. Myonuclei in isolated DAPI-stained fibres (<italic>n</italic>&#8201;=&#8201;160, four animals per group, 40 fibres per animal) harvested from tibialis anterior of 10-week-old control (<italic>Ct</italic>) and PPAR&#946; transgenic (<italic>Tg</italic>) B6D2F1 mice were quantified and pooled using ascendant hierarchical classification in three groups of fibres containing (1) less than 85 nuclei, (2) from 85 to 100 nuclei and (3) more than 100 nuclei/mm of fibre length. Percentage of each group, mean number of nuclei in each group (<italic>Mean</italic>) and standard deviation (<italic>s.d.</italic>) are reported for control (<italic>Ct</italic>) and PPAR&#946; transgenic (<italic>Tg</italic>) mice</p></caption>
###xml 2226 2226 2192 2192 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="424_2009_676_Fig1_HTML" id="MO1"/>
###xml 1178 2226 1159 2192 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="40">Muscle-specific PPAR&#946; over-expression promotes an increase of myonuclear density. <bold>a</bold> Representative isolated DAPI-stained fibres harvested from tibialis anterior of 10-week-old control (<italic>Ct</italic>) and PPAR&#946; transgenic (<italic>Tg</italic>) B6D2 mice. Global myonuclear density is indicated as myonuclei number per millimetre of fibre length (<italic>n</italic>&#8201;=&#8201;160, four animals per group, 40 fibres per animal). <bold>b</bold> Distribution of myofibres population in TLA from control and PPAR&#946; overexpressing mice. Myonuclei in isolated DAPI-stained fibres (<italic>n</italic>&#8201;=&#8201;160, four animals per group, 40 fibres per animal) harvested from tibialis anterior of 10-week-old control (<italic>Ct</italic>) and PPAR&#946; transgenic (<italic>Tg</italic>) B6D2F1 mice were quantified and pooled using ascendant hierarchical classification in three groups of fibres containing (1) less than 85 nuclei, (2) from 85 to 100 nuclei and (3) more than 100 nuclei/mm of fibre length. Percentage of each group, mean number of nuclei in each group (<italic>Mean</italic>) and standard deviation (<italic>s.d.</italic>) are reported for control (<italic>Ct</italic>) and PPAR&#946; transgenic (<italic>Tg</italic>) mice</p></caption><graphic position="anchor" xlink:href="424_2009_676_Fig1_HTML" id="MO1"/></fig>
###xml 265 280 <span type="species:ncbi:10090">transgenic mice</span>
###xml 562 577 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1410 1414 <span type="species:ncbi:10090">mice</span>
###xml 1650 1654 <span type="species:ncbi:10090">mice</span>
###xml 1851 1855 <span type="species:ncbi:10090">mice</span>
###xml 2222 2226 <span type="species:ncbi:10090">mice</span>
The effects of PPARbeta over-expression on myonuclear density were first investigated by quantification of myonuclear number per millimetre of fibre length in diamidino-2-phenyl-indole (DAPI)-stained isolated fibres, prepared from TLA muscle of adult B6D2 PPARbeta transgenic mice and control littermates (Tg and Ct; Fig. 1a). These experiments revealed that muscle-specific PPARbeta over-expression leads to a 14% increase of nuclei number per millimetre of fibre length (92 +/- 1.32, n = 160 fibres for controls versus 105 +/- 3.2, n = 160 fibres for PPARbeta transgenic mice, p = 0.003). Using ascendant hierarchical classification, we defined three groups of myofibres, i.e. those containing less than 85 nuclei/mm (F < 85), those containing a number of nuclei comprised between 85 and 100 nuclei/mm (85 < F < 100) and those containing more than 100 nuclei/mm (F > 100). As shown in Fig. 1b, PPARbeta over-expression induced major changes in myofibre distribution in these three groups with reduction of myofibre numbers in both the F < 85 (31% to 10%) and 85 < F < 100 (41% to 35%) groups, while the number of fibres in the F > 100 group is notably increased (28% to 55%). Fig. 1Muscle-specific PPARbeta over-expression promotes an increase of myonuclear density. a Representative isolated DAPI-stained fibres harvested from tibialis anterior of 10-week-old control (Ct) and PPARbeta transgenic (Tg) B6D2 mice. Global myonuclear density is indicated as myonuclei number per millimetre of fibre length (n = 160, four animals per group, 40 fibres per animal). b Distribution of myofibres population in TLA from control and PPARbeta overexpressing mice. Myonuclei in isolated DAPI-stained fibres (n = 160, four animals per group, 40 fibres per animal) harvested from tibialis anterior of 10-week-old control (Ct) and PPARbeta transgenic (Tg) B6D2F1 mice were quantified and pooled using ascendant hierarchical classification in three groups of fibres containing (1) less than 85 nuclei, (2) from 85 to 100 nuclei and (3) more than 100 nuclei/mm of fibre length. Percentage of each group, mean number of nuclei in each group (Mean) and standard deviation (s.d.) are reported for control (Ct) and PPARbeta transgenic (Tg) mice
###end p 39
###begin p 40
###xml 85 86 82 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 188 190 185 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 217 219 211 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tg</italic>
###xml 323 324 317 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 379 380 373 374 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 515 516 506 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 627 629 618 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 656 658 644 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tg</italic>
###xml 943 947 931 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mean</italic>
###xml 973 977 961 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink">s.d.</italic>
###xml 1005 1007 993 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 1034 1036 1019 1021 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tg</italic>
###xml 226 230 <span type="species:ncbi:10090">mice</span>
###xml 466 470 <span type="species:ncbi:10090">mice</span>
###xml 667 671 <span type="species:ncbi:10090">mice</span>
###xml 1038 1042 <span type="species:ncbi:10090">mice</span>
Muscle-specific PPARbeta over-expression promotes an increase of myonuclear density. a Representative isolated DAPI-stained fibres harvested from tibialis anterior of 10-week-old control (Ct) and PPARbeta transgenic (Tg) B6D2 mice. Global myonuclear density is indicated as myonuclei number per millimetre of fibre length (n = 160, four animals per group, 40 fibres per animal). b Distribution of myofibres population in TLA from control and PPARbeta overexpressing mice. Myonuclei in isolated DAPI-stained fibres (n = 160, four animals per group, 40 fibres per animal) harvested from tibialis anterior of 10-week-old control (Ct) and PPARbeta transgenic (Tg) B6D2F1 mice were quantified and pooled using ascendant hierarchical classification in three groups of fibres containing (1) less than 85 nuclei, (2) from 85 to 100 nuclei and (3) more than 100 nuclei/mm of fibre length. Percentage of each group, mean number of nuclei in each group (Mean) and standard deviation (s.d.) are reported for control (Ct) and PPARbeta transgenic (Tg) mice
###end p 40
###begin p 41
###xml 177 179 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">38</xref>
###xml 553 554 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 564 565 554 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 802 803 789 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 870 871 857 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 922 923 909 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1236 1237 1217 1218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1395 1396 1376 1377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1466 1467 1447 1448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1534 1535 1515 1516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1539 1545 1520 1526 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1624 1625 1602 1603 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1694 1695 1672 1673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1856 1858 1834 1836 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 1895 1897 1870 1872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1d</italic>
###xml 1908 1910 1883 1885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2d</italic>
###xml 1924 1926 1899 1901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4d</italic>
###xml 1931 1932 1906 1907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1980 1982 1955 1957 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 1985 1997 1960 1972 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pound sign p</italic>
###xml 2049 2051 2024 2026 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1d</italic>
###xml 2054 2055 2029 2030 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2104 2105 2079 2080 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 2147 2149 2122 2124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1b</xref>
###xml 2214 2218 2189 2193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mean</italic>
###xml 2244 2248 2219 2223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">s.d.</italic>
###xml 1545 2303 1526 2278 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="42">PPAR&#946; pharmacological activation induces an increase of myonuclear density. <bold>a</bold> Quantification of myonuclei number in isolated DAPI-stained fibres (<italic>n</italic>&#8201;=&#8201;160, four animals per group, 40 fibres per animal) harvested from tibialis anterior of 10-week-old C57Bl6 mice for different times of treatment with vehicle (<italic>Ct</italic>) or PPAR&#946; agonist GW0742 (1&#160;day (<italic>1d</italic>), 2&#160;days (<italic>2d</italic>) and 4&#160;days (<italic>4d</italic>)). *<italic>p</italic>&#8201;&lt;&#8201;0.001, different from vehicle-treated group (<italic>Ct</italic>); <italic>pound sign p</italic>&#8201;&lt;&#8201;0.01, different from 1&#160;day treated animal group (<italic>1d</italic>). <bold>b</bold> Distribution of myofibres population counted in <bold>a</bold> using the same classification as in Fig.&#160;<xref rid="Fig1" ref-type="fig">1b</xref>. Percentage of each group, mean number of nuclei in each group (<italic>Mean</italic>) and standard deviation (<italic>s.d.</italic>) are reported for each period of treatment with GW0742</p>
###xml 1545 2303 1526 2278 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="42">PPAR&#946; pharmacological activation induces an increase of myonuclear density. <bold>a</bold> Quantification of myonuclei number in isolated DAPI-stained fibres (<italic>n</italic>&#8201;=&#8201;160, four animals per group, 40 fibres per animal) harvested from tibialis anterior of 10-week-old C57Bl6 mice for different times of treatment with vehicle (<italic>Ct</italic>) or PPAR&#946; agonist GW0742 (1&#160;day (<italic>1d</italic>), 2&#160;days (<italic>2d</italic>) and 4&#160;days (<italic>4d</italic>)). *<italic>p</italic>&#8201;&lt;&#8201;0.001, different from vehicle-treated group (<italic>Ct</italic>); <italic>pound sign p</italic>&#8201;&lt;&#8201;0.01, different from 1&#160;day treated animal group (<italic>1d</italic>). <bold>b</bold> Distribution of myofibres population counted in <bold>a</bold> using the same classification as in Fig.&#160;<xref rid="Fig1" ref-type="fig">1b</xref>. Percentage of each group, mean number of nuclei in each group (<italic>Mean</italic>) and standard deviation (<italic>s.d.</italic>) are reported for each period of treatment with GW0742</p></caption>
###xml 2303 2303 2278 2278 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="424_2009_676_Fig2_HTML" id="MO2"/>
###xml 1539 2303 1520 2278 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="42">PPAR&#946; pharmacological activation induces an increase of myonuclear density. <bold>a</bold> Quantification of myonuclei number in isolated DAPI-stained fibres (<italic>n</italic>&#8201;=&#8201;160, four animals per group, 40 fibres per animal) harvested from tibialis anterior of 10-week-old C57Bl6 mice for different times of treatment with vehicle (<italic>Ct</italic>) or PPAR&#946; agonist GW0742 (1&#160;day (<italic>1d</italic>), 2&#160;days (<italic>2d</italic>) and 4&#160;days (<italic>4d</italic>)). *<italic>p</italic>&#8201;&lt;&#8201;0.001, different from vehicle-treated group (<italic>Ct</italic>); <italic>pound sign p</italic>&#8201;&lt;&#8201;0.01, different from 1&#160;day treated animal group (<italic>1d</italic>). <bold>b</bold> Distribution of myofibres population counted in <bold>a</bold> using the same classification as in Fig.&#160;<xref rid="Fig1" ref-type="fig">1b</xref>. Percentage of each group, mean number of nuclei in each group (<italic>Mean</italic>) and standard deviation (<italic>s.d.</italic>) are reported for each period of treatment with GW0742</p></caption><graphic position="anchor" xlink:href="424_2009_676_Fig2_HTML" id="MO2"/></fig>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 425 429 <span type="species:ncbi:10090">mice</span>
###xml 528 532 <span type="species:ncbi:10090">mice</span>
###xml 1033 1048 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1804 1808 <span type="species:ncbi:10090">mice</span>
We then investigated the effects of pharmacological PPARbeta activation on myonuclear density by treating 10-week-old C57Bl6 male mice with GW0742, a PPARbeta-specific agonist [38]. The number of myonuclei/mm fibre length was determined at increasing times after GW0742 or vehicle injections. We first noticed a significant strain difference concerning the myonuclear density (92 +/- 1.32 and 86 +/- 1.40, in B6D2 and C57Bl6 mice, respectively) as well as the distribution in the three predefined groups between B6D2 and C57Bl6 mice (compare Ct in Fig. 1b to Fig. 2b). As expected, vehicle treatment did not affect myonuclear density nor distribution in the three predefined groups of fibres (not shown). On the contrary, PPARbeta activation promoted a fast increase in myonuclear density with an 11% (p < 0.0001) increase after 1 day and a maximal augmentation of 20% (p < 0.0001) reached after 2 days of treatment (Fig. 2a). Classification of fibres in the three predefined groups revealed that, as previously observed in PPARbeta transgenic mice, pharmacological PPARbeta activation resulted in time-dependent and notable changes in fibre group distribution in favour of fibres with a high myonuclear density. This shift towards the F > 100 group is progressive from 8% to 34% after 1 day and to a maximum of 62% reached after 2 days, with a parallel decrease of percentage of fibres in both F < 85 group (47% to 28% after 1 day and to 15% after 2 days) and 85 < F < 100 group (45% to 38% after 1 day and to 23% after 2 days; Fig. 2b). Fig. 2PPARbeta pharmacological activation induces an increase of myonuclear density. a Quantification of myonuclei number in isolated DAPI-stained fibres (n = 160, four animals per group, 40 fibres per animal) harvested from tibialis anterior of 10-week-old C57Bl6 mice for different times of treatment with vehicle (Ct) or PPARbeta agonist GW0742 (1 day (1d), 2 days (2d) and 4 days (4d)). *p < 0.001, different from vehicle-treated group (Ct); pound sign p < 0.01, different from 1 day treated animal group (1d). b Distribution of myofibres population counted in a using the same classification as in Fig. 1b. Percentage of each group, mean number of nuclei in each group (Mean) and standard deviation (s.d.) are reported for each period of treatment with GW0742
###end p 41
###begin p 42
###xml 79 80 76 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 149 150 146 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 311 313 308 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 350 352 344 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1d</italic>
###xml 363 365 357 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2d</italic>
###xml 379 381 373 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4d</italic>
###xml 386 387 380 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 435 437 429 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 440 452 434 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pound sign p</italic>
###xml 504 506 498 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1d</italic>
###xml 509 510 503 504 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 559 560 553 554 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 602 604 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1b</xref>
###xml 669 673 663 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mean</italic>
###xml 699 703 693 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">s.d.</italic>
###xml 259 263 <span type="species:ncbi:10090">mice</span>
PPARbeta pharmacological activation induces an increase of myonuclear density. a Quantification of myonuclei number in isolated DAPI-stained fibres (n = 160, four animals per group, 40 fibres per animal) harvested from tibialis anterior of 10-week-old C57Bl6 mice for different times of treatment with vehicle (Ct) or PPARbeta agonist GW0742 (1 day (1d), 2 days (2d) and 4 days (4d)). *p < 0.001, different from vehicle-treated group (Ct); pound sign p < 0.01, different from 1 day treated animal group (1d). b Distribution of myofibres population counted in a using the same classification as in Fig. 1b. Percentage of each group, mean number of nuclei in each group (Mean) and standard deviation (s.d.) are reported for each period of treatment with GW0742
###end p 42
###begin title 43
Pharmacological PPARbeta activation does not promote cell division in TLA muscle
###end title 43
###begin p 44
###xml 713 714 707 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 820 821 814 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 842 843 836 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 986 987 977 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 1002 1003 993 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 1021 1022 1012 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 1184 1185 1172 1173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 1387 1388 1372 1373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 1419 1425 1404 1410 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 1597 1598 1582 1583 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1640 1641 1625 1626 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1643 1644 1628 1629 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 1698 1699 1683 1684 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1700 1701 1685 1686 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 1775 1776 1760 1761 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1778 1779 1763 1764 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 1785 1786 1770 1771 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1788 1789 1773 1774 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 1796 1797 1781 1782 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 1799 1800 1784 1785 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 1802 1803 1787 1788 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 1992 1998 1977 1983 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 2002 2003 1987 1988 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 2005 2006 1990 1991 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 2007 2008 1992 1993 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 2045 2046 2030 2031 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 2112 2121 2097 2106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowhead</italic>
###xml 2125 2126 2110 2111 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 2128 2129 2113 2114 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 1425 2150 1410 2134 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="45">GW0742-promoted myonuclear remodelling is independent of cell proliferation in tibialis anterior. Immunohistochemical localization of PCNA, a well-known mitotic marker, in <bold>a</bold> section of duodenum as positive control, <bold>b</bold>, <bold>g</bold> section of TLA muscles from vehicle-treated animals, <bold>c</bold>&#8211;<bold>j</bold> sections of TLA muscles from animals receiving GW0742 for various times: <bold>c</bold>, <bold>h</bold> 5&#160;h, <bold>d</bold>, <bold>i</bold> 24&#160;h, <bold>e</bold>, <bold>f</bold>, <bold>j</bold> 48&#160;h. Note the important labelling in the crypts and the quasi absence of positive myonuclei in both control and GW0742-treated animals. PCNA signals were often detected in blood vessels (<italic>arrows</italic> in <bold>d</bold>, <bold>h</bold>&#8211;<bold>j</bold>) but rarely in myonuclei (arrows in <bold>c</bold>). Finally, note the elevated number of centrally located nuclei (<italic>arrowhead</italic> in <bold>e</bold>, <bold>f</bold>). Scale bars, 50&#160;&#956;m</p>
###xml 1425 2150 1410 2134 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="45">GW0742-promoted myonuclear remodelling is independent of cell proliferation in tibialis anterior. Immunohistochemical localization of PCNA, a well-known mitotic marker, in <bold>a</bold> section of duodenum as positive control, <bold>b</bold>, <bold>g</bold> section of TLA muscles from vehicle-treated animals, <bold>c</bold>&#8211;<bold>j</bold> sections of TLA muscles from animals receiving GW0742 for various times: <bold>c</bold>, <bold>h</bold> 5&#160;h, <bold>d</bold>, <bold>i</bold> 24&#160;h, <bold>e</bold>, <bold>f</bold>, <bold>j</bold> 48&#160;h. Note the important labelling in the crypts and the quasi absence of positive myonuclei in both control and GW0742-treated animals. PCNA signals were often detected in blood vessels (<italic>arrows</italic> in <bold>d</bold>, <bold>h</bold>&#8211;<bold>j</bold>) but rarely in myonuclei (arrows in <bold>c</bold>). Finally, note the elevated number of centrally located nuclei (<italic>arrowhead</italic> in <bold>e</bold>, <bold>f</bold>). Scale bars, 50&#160;&#956;m</p></caption>
###xml 2150 2150 2134 2134 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="424_2009_676_Fig3_HTML" id="MO3"/>
###xml 1419 2150 1404 2134 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="45">GW0742-promoted myonuclear remodelling is independent of cell proliferation in tibialis anterior. Immunohistochemical localization of PCNA, a well-known mitotic marker, in <bold>a</bold> section of duodenum as positive control, <bold>b</bold>, <bold>g</bold> section of TLA muscles from vehicle-treated animals, <bold>c</bold>&#8211;<bold>j</bold> sections of TLA muscles from animals receiving GW0742 for various times: <bold>c</bold>, <bold>h</bold> 5&#160;h, <bold>d</bold>, <bold>i</bold> 24&#160;h, <bold>e</bold>, <bold>f</bold>, <bold>j</bold> 48&#160;h. Note the important labelling in the crypts and the quasi absence of positive myonuclei in both control and GW0742-treated animals. PCNA signals were often detected in blood vessels (<italic>arrows</italic> in <bold>d</bold>, <bold>h</bold>&#8211;<bold>j</bold>) but rarely in myonuclei (arrows in <bold>c</bold>). Finally, note the elevated number of centrally located nuclei (<italic>arrowhead</italic> in <bold>e</bold>, <bold>f</bold>). Scale bars, 50&#160;&#956;m</p></caption><graphic position="anchor" xlink:href="424_2009_676_Fig3_HTML" id="MO3"/></fig>
The fast and important increase in myonuclear density as well as hyperplasia suggests major events of MPC activation and fusion to myofibres. However, the quickness of myonuclear accretion in response to PPARbeta activation argues against a process requiring cell proliferation. To investigate directly the effect of PPARbeta activation on cell proliferation in TLA muscle, we explored by immunochemistry the expression of a well-known mitosis marker, the proliferating cell nuclear antigen (PCNA), in muscles from animals receiving or not GW0742 for various times. Sections of the duodenum from control animals were used as positive control and displayed, as expected, an important labelling in the crypts (Fig. 3a). In contrast, nearly no PCNA-positive myonuclei were detectable in sections from control animals (Fig. 3b). As shown in Fig. 3, PPARbeta activation did not increase the number of PCNA-positive myonuclei, whatever the period of treatment with GW0742 was, i.e. 5 h (Fig. 3c), 24 h (Fig. 3d), or 48 h (Fig. 3e, f). However, after 48 h of PPARbeta agonist treatment, several fibres with centrally located myonuclei can be observed as a mark of myonuclear accretion (Fig. 3e and f). These results suggest that PPARbeta-promoted myonuclear accretion did not involve proliferation of MPCs. Finally, we did detect some PCNA-positive cells but almost only in blood vessels (Fig. 3d, h-j at high magnification). Fig. 3GW0742-promoted myonuclear remodelling is independent of cell proliferation in tibialis anterior. Immunohistochemical localization of PCNA, a well-known mitotic marker, in a section of duodenum as positive control, b, g section of TLA muscles from vehicle-treated animals, c-j sections of TLA muscles from animals receiving GW0742 for various times: c, h 5 h, d, i 24 h, e, f, j 48 h. Note the important labelling in the crypts and the quasi absence of positive myonuclei in both control and GW0742-treated animals. PCNA signals were often detected in blood vessels (arrows in d, h-j) but rarely in myonuclei (arrows in c). Finally, note the elevated number of centrally located nuclei (arrowhead in e, f). Scale bars, 50 mum
###end p 44
###begin p 45
###xml 172 173 172 173 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 215 216 215 216 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 218 219 218 219 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 273 274 273 274 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 275 276 275 276 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 350 351 350 351 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 353 354 353 354 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 360 361 360 361 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 363 364 363 364 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 371 372 371 372 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 374 375 374 375 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 377 378 377 378 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 567 573 567 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 577 578 577 578 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 580 581 580 581 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 582 583 582 583 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 620 621 620 621 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 687 696 687 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowhead</italic>
###xml 700 701 700 701 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 703 704 703 704 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
GW0742-promoted myonuclear remodelling is independent of cell proliferation in tibialis anterior. Immunohistochemical localization of PCNA, a well-known mitotic marker, in a section of duodenum as positive control, b, g section of TLA muscles from vehicle-treated animals, c-j sections of TLA muscles from animals receiving GW0742 for various times: c, h 5 h, d, i 24 h, e, f, j 48 h. Note the important labelling in the crypts and the quasi absence of positive myonuclei in both control and GW0742-treated animals. PCNA signals were often detected in blood vessels (arrows in d, h-j) but rarely in myonuclei (arrows in c). Finally, note the elevated number of centrally located nuclei (arrowhead in e, f). Scale bars, 50 mum
###end p 45
###begin p 46
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 481 482 481 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 560 561 560 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 580 581 580 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 866 867 866 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 948 949 948 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 976 977 976 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 1463 1464 1460 1461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 1791 1797 1785 1791 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 1952 1953 1946 1947 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1955 1956 1949 1950 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1973 1974 1967 1968 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1975 1976 1969 1970 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 1999 2000 1993 1994 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2011 2012 2005 2006 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 2014 2015 2008 2009 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 2016 2017 2010 2011 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 2222 2223 2216 2217 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 2225 2226 2219 2220 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 2228 2229 2222 2223 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 2294 2315 2288 2309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec9" ref-type="sec">Materials and methods</xref>
###xml 2401 2402 2395 2396 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 2404 2405 2398 2399 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 2408 2418 2402 2412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arrowheads</italic>
###xml 2460 2461 2454 2455 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 2463 2464 2457 2458 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 2523 2524 2517 2518 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2526 2527 2520 2521 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 2529 2530 2523 2524 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 2549 2570 2543 2564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec9" ref-type="sec">Materials and methods</xref>
###xml 2656 2657 2650 2651 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 2672 2673 2666 2667 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 2766 2767 2760 2761 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 2769 2770 2763 2764 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 2772 2773 2766 2767 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 2849 2850 2843 2844 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2862 2863 2856 2857 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1797 2901 1791 2894 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="47">GW0742-promoted myonuclear remodelling does not require cell division in tibialis anterior. Mice were injected with BrdU and or not with GW0742. Duodenum (<bold>a</bold>, <bold>b</bold>) or TLA muscle (<bold>c</bold>&#8211;<bold>f</bold>) harvested from 24&#160;h (<bold>b</bold>) or 48&#160;h (<bold>a</bold>, <bold>c</bold>&#8211;<bold>f</bold>) post GW0742 treatment, were either frozen in tissue-embedding medium or fixed, dehydrated and embedded in paraffin. Frozen sections on slides were stained with anti-BrdU antibody coupled to fluorescein (<bold>a</bold>, <bold>c</bold>, <bold>e</bold>) and mounted using Vectashield containing DAPI as described in &#8220;<xref rid="Sec9" ref-type="sec">Materials and methods</xref>&#8221;. Positive cells are detected in blood vessels, and very few myonuclei are labelled (<bold>c</bold>, <bold>e</bold>). <italic>Arrowheads</italic> indicate myofibres with central nucleus (<bold>c</bold>, <bold>e</bold>). Paraffin sections were stained with anti-BrdU antibody (<bold>b</bold>, <bold>d</bold>, <bold>f</bold>) as described in &#8220;<xref rid="Sec9" ref-type="sec">Materials and methods</xref>&#8221;, and nuclei were counterstained with haematoxylin. Very few myonuclei are labelled (<bold>d</bold>, and arrow in <bold>f</bold>); on the contrary, a large number of myofibres with one or more central nuclei are visible (<bold>d</bold>, <bold>e</bold>, <bold>f</bold>). Note the increased BrdU labelling in the duodenum sections between 24&#160;h (<bold>b</bold>) and 48&#160;h (<bold>a</bold>) of the BrdU pulse. Scale bar, 50&#160;&#956;m</p>
###xml 1797 2901 1791 2894 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="47">GW0742-promoted myonuclear remodelling does not require cell division in tibialis anterior. Mice were injected with BrdU and or not with GW0742. Duodenum (<bold>a</bold>, <bold>b</bold>) or TLA muscle (<bold>c</bold>&#8211;<bold>f</bold>) harvested from 24&#160;h (<bold>b</bold>) or 48&#160;h (<bold>a</bold>, <bold>c</bold>&#8211;<bold>f</bold>) post GW0742 treatment, were either frozen in tissue-embedding medium or fixed, dehydrated and embedded in paraffin. Frozen sections on slides were stained with anti-BrdU antibody coupled to fluorescein (<bold>a</bold>, <bold>c</bold>, <bold>e</bold>) and mounted using Vectashield containing DAPI as described in &#8220;<xref rid="Sec9" ref-type="sec">Materials and methods</xref>&#8221;. Positive cells are detected in blood vessels, and very few myonuclei are labelled (<bold>c</bold>, <bold>e</bold>). <italic>Arrowheads</italic> indicate myofibres with central nucleus (<bold>c</bold>, <bold>e</bold>). Paraffin sections were stained with anti-BrdU antibody (<bold>b</bold>, <bold>d</bold>, <bold>f</bold>) as described in &#8220;<xref rid="Sec9" ref-type="sec">Materials and methods</xref>&#8221;, and nuclei were counterstained with haematoxylin. Very few myonuclei are labelled (<bold>d</bold>, and arrow in <bold>f</bold>); on the contrary, a large number of myofibres with one or more central nuclei are visible (<bold>d</bold>, <bold>e</bold>, <bold>f</bold>). Note the increased BrdU labelling in the duodenum sections between 24&#160;h (<bold>b</bold>) and 48&#160;h (<bold>a</bold>) of the BrdU pulse. Scale bar, 50&#160;&#956;m</p></caption>
###xml 2901 2901 2894 2894 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="424_2009_676_Fig4_HTML" id="MO4"/>
###xml 1791 2901 1785 2894 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="47">GW0742-promoted myonuclear remodelling does not require cell division in tibialis anterior. Mice were injected with BrdU and or not with GW0742. Duodenum (<bold>a</bold>, <bold>b</bold>) or TLA muscle (<bold>c</bold>&#8211;<bold>f</bold>) harvested from 24&#160;h (<bold>b</bold>) or 48&#160;h (<bold>a</bold>, <bold>c</bold>&#8211;<bold>f</bold>) post GW0742 treatment, were either frozen in tissue-embedding medium or fixed, dehydrated and embedded in paraffin. Frozen sections on slides were stained with anti-BrdU antibody coupled to fluorescein (<bold>a</bold>, <bold>c</bold>, <bold>e</bold>) and mounted using Vectashield containing DAPI as described in &#8220;<xref rid="Sec9" ref-type="sec">Materials and methods</xref>&#8221;. Positive cells are detected in blood vessels, and very few myonuclei are labelled (<bold>c</bold>, <bold>e</bold>). <italic>Arrowheads</italic> indicate myofibres with central nucleus (<bold>c</bold>, <bold>e</bold>). Paraffin sections were stained with anti-BrdU antibody (<bold>b</bold>, <bold>d</bold>, <bold>f</bold>) as described in &#8220;<xref rid="Sec9" ref-type="sec">Materials and methods</xref>&#8221;, and nuclei were counterstained with haematoxylin. Very few myonuclei are labelled (<bold>d</bold>, and arrow in <bold>f</bold>); on the contrary, a large number of myofibres with one or more central nuclei are visible (<bold>d</bold>, <bold>e</bold>, <bold>f</bold>). Note the increased BrdU labelling in the duodenum sections between 24&#160;h (<bold>b</bold>) and 48&#160;h (<bold>a</bold>) of the BrdU pulse. Scale bar, 50&#160;&#956;m</p></caption><graphic position="anchor" xlink:href="424_2009_676_Fig4_HTML" id="MO4"/></fig>
###xml 1889 1893 <span type="species:ncbi:10090">Mice</span>
To confirm these observations, bromodeoxyuridine (BrdU) incorporation into DNA was used. In vivo BrdU labelling technique allows identification of MPCs that have proliferated, migrated and either incorporated into existing myofibres or having been implicated in the formation of new fibres [16, 35]. BrdU incorporation into DNA was determined by two different methods, indirect immunofluorescence on cryosections and immunochemistry on paraffin-embedded sections. As shown in Fig. 4a, b, sections from the duodenum of control animals that received for 1 (Fig. 4b) or 2 days (Fig. 4a) daily injections of BrdU validated the method to follow cell proliferation in vivo, as BrdU-positive cells are detected both in crypts, where the cells are proliferating, and in the lower parts of the villi that contain epithelial cells, which have proliferated in the crypts (Fig. 4b) and then migrated during their differentiation towards the villous apex (Fig. 4a). Data presented in Fig. 4 confirmed that PPARbeta-promoted muscle remodelling does not implicate cell proliferation as the number of BrdU-positive nuclei remained very low in muscle from animals treated for 2 days with GW0742. Less than 1% of nuclei were BrdU-positive, and no significant difference was found compared to muscles from untreated animals. Furthermore, as previously observed, several myofibres containing central nuclei can be evidenced in muscles from animals treated for 48 h with GW0742 (Fig. 4c, e, f). Interestingly, these nuclei remained BrdU-negative. As central nuclei are marks of the fusion of MPCs to fibres and/or newly formed myofibres, these observations also strongly support the conclusion that myonuclear accretion and fibre hyperplasia promoted by PPARbeta activation took place without MPC proliferation. Fig. 4GW0742-promoted myonuclear remodelling does not require cell division in tibialis anterior. Mice were injected with BrdU and or not with GW0742. Duodenum (a, b) or TLA muscle (c-f) harvested from 24 h (b) or 48 h (a, c-f) post GW0742 treatment, were either frozen in tissue-embedding medium or fixed, dehydrated and embedded in paraffin. Frozen sections on slides were stained with anti-BrdU antibody coupled to fluorescein (a, c, e) and mounted using Vectashield containing DAPI as described in "Materials and methods". Positive cells are detected in blood vessels, and very few myonuclei are labelled (c, e). Arrowheads indicate myofibres with central nucleus (c, e). Paraffin sections were stained with anti-BrdU antibody (b, d, f) as described in "Materials and methods", and nuclei were counterstained with haematoxylin. Very few myonuclei are labelled (d, and arrow in f); on the contrary, a large number of myofibres with one or more central nuclei are visible (d, e, f). Note the increased BrdU labelling in the duodenum sections between 24 h (b) and 48 h (a) of the BrdU pulse. Scale bar, 50 mum
###end p 46
###begin p 47
###xml 155 156 155 156 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 158 159 158 159 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 176 177 176 177 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 178 179 178 179 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 202 203 202 203 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 214 215 214 215 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 217 218 217 218 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 219 220 219 220 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 425 426 425 426 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 428 429 428 429 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 431 432 431 432 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 497 518 497 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec9" ref-type="sec">Materials and methods</xref>
###xml 604 605 604 605 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 607 608 607 608 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 611 621 611 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arrowheads</italic>
###xml 663 664 663 664 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 666 667 666 667 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 726 727 726 727 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 729 730 729 730 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 732 733 732 733 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 752 773 752 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec9" ref-type="sec">Materials and methods</xref>
###xml 859 860 859 860 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 875 876 875 876 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 969 970 969 970 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 972 973 972 973 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 975 976 975 976 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 1052 1053 1052 1053 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1065 1066 1065 1066 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 92 96 <span type="species:ncbi:10090">Mice</span>
GW0742-promoted myonuclear remodelling does not require cell division in tibialis anterior. Mice were injected with BrdU and or not with GW0742. Duodenum (a, b) or TLA muscle (c-f) harvested from 24 h (b) or 48 h (a, c-f) post GW0742 treatment, were either frozen in tissue-embedding medium or fixed, dehydrated and embedded in paraffin. Frozen sections on slides were stained with anti-BrdU antibody coupled to fluorescein (a, c, e) and mounted using Vectashield containing DAPI as described in "Materials and methods". Positive cells are detected in blood vessels, and very few myonuclei are labelled (c, e). Arrowheads indicate myofibres with central nucleus (c, e). Paraffin sections were stained with anti-BrdU antibody (b, d, f) as described in "Materials and methods", and nuclei were counterstained with haematoxylin. Very few myonuclei are labelled (d, and arrow in f); on the contrary, a large number of myofibres with one or more central nuclei are visible (d, e, f). Note the increased BrdU labelling in the duodenum sections between 24 h (b) and 48 h (a) of the BrdU pulse. Scale bar, 50 mum
###end p 47
###begin title 48
Positive effects of PPARbeta activation on myonuclear density are dependent of the calcineurin/NFAT pathway
###end title 48
###begin p 49
###xml 166 168 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 159 164 <span type="species:ncbi:10090">mouse</span>
###xml 463 467 <span type="species:ncbi:10090">mice</span>
We previously provided evidences that the active calcineurin pathway is required for the myogenic and angiogenic responses to PPARbeta activation in the adult mouse [10]. To test whether an active calcineurin pathway was required for the PPARbeta-promoted myonuclear accretion, we explored the effects of co-administration of cyclosporine A (CsA), a potent inhibitor of calcineurin/nuclear factor of activated T-cells (NFAT) pathway, on TLA myonuclear density in mice treated by GW0742 for 2 days.
###end p 49
###begin p 50
###xml 17 18 17 18 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 345 346 342 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 584 585 581 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 589 595 586 592 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;5</label>
###xml 673 674 667 668 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 803 804 797 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 888 890 882 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 909 912 903 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CsA</italic>
###xml 940 942 931 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2d</italic>
###xml 991 999 979 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2d&#8201;+&#8201;CsA</italic>
###xml 1003 1004 991 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1057 1058 1045 1046 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1107 1108 1095 1096 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1150 1152 1138 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1b</xref>
###xml 1217 1221 1205 1209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mean</italic>
###xml 1247 1251 1235 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">s.d.</italic>
###xml 595 1284 592 1272 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="51">Positive effects of PPAR&#946; on myonuclear density are calcineurin dependent. <bold>a</bold> Quantification of nuclei number in isolated DAPI-stained fibres harvested from tibialis anterior of 10-week-old C57Bl6 animals (<italic>n</italic>&#8201;=&#8201;160, four animals per group, 40 fibres per animal), treated 2&#160;days with vehicle (<italic>Ct</italic>), cyclosporine A (<italic>CsA</italic>), PPAR&#946; agonist GW0742 (<italic>2d</italic>) or PPAR&#946; agonist GW0742 and cyclosporine A (<italic>2d&#8201;+&#8201;CsA</italic>). *<italic>p</italic>&#8201;&lt;&#8201;0.01, different from Ct, CsA and 2d&#8201;+&#8201;CsA groups. <bold>b</bold> Distribution of myofibres population counted in <bold>a</bold> using the same classification as in Fig.&#160;<xref rid="Fig1" ref-type="fig">1b</xref>. Percentage of each group, mean number of nuclei in each group (<italic>Mean</italic>) and standard deviation (<italic>s.d.</italic>) are reported for each treatment</p>
###xml 595 1284 592 1272 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="51">Positive effects of PPAR&#946; on myonuclear density are calcineurin dependent. <bold>a</bold> Quantification of nuclei number in isolated DAPI-stained fibres harvested from tibialis anterior of 10-week-old C57Bl6 animals (<italic>n</italic>&#8201;=&#8201;160, four animals per group, 40 fibres per animal), treated 2&#160;days with vehicle (<italic>Ct</italic>), cyclosporine A (<italic>CsA</italic>), PPAR&#946; agonist GW0742 (<italic>2d</italic>) or PPAR&#946; agonist GW0742 and cyclosporine A (<italic>2d&#8201;+&#8201;CsA</italic>). *<italic>p</italic>&#8201;&lt;&#8201;0.01, different from Ct, CsA and 2d&#8201;+&#8201;CsA groups. <bold>b</bold> Distribution of myofibres population counted in <bold>a</bold> using the same classification as in Fig.&#160;<xref rid="Fig1" ref-type="fig">1b</xref>. Percentage of each group, mean number of nuclei in each group (<italic>Mean</italic>) and standard deviation (<italic>s.d.</italic>) are reported for each treatment</p></caption>
###xml 1284 1284 1272 1272 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="424_2009_676_Fig5_HTML" id="MO5"/>
###xml 589 1284 586 1272 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig5"><label>Fig.&#160;5</label><caption><p textid="51">Positive effects of PPAR&#946; on myonuclear density are calcineurin dependent. <bold>a</bold> Quantification of nuclei number in isolated DAPI-stained fibres harvested from tibialis anterior of 10-week-old C57Bl6 animals (<italic>n</italic>&#8201;=&#8201;160, four animals per group, 40 fibres per animal), treated 2&#160;days with vehicle (<italic>Ct</italic>), cyclosporine A (<italic>CsA</italic>), PPAR&#946; agonist GW0742 (<italic>2d</italic>) or PPAR&#946; agonist GW0742 and cyclosporine A (<italic>2d&#8201;+&#8201;CsA</italic>). *<italic>p</italic>&#8201;&lt;&#8201;0.01, different from Ct, CsA and 2d&#8201;+&#8201;CsA groups. <bold>b</bold> Distribution of myofibres population counted in <bold>a</bold> using the same classification as in Fig.&#160;<xref rid="Fig1" ref-type="fig">1b</xref>. Percentage of each group, mean number of nuclei in each group (<italic>Mean</italic>) and standard deviation (<italic>s.d.</italic>) are reported for each treatment</p></caption><graphic position="anchor" xlink:href="424_2009_676_Fig5_HTML" id="MO5"/></fig>
As shown in Fig. 5a, b, CsA administration alone neither affected the myonuclear density nor the distribution in the three defined fibre groups. On the contrary, CsA administration totally blunted the PPARbeta-dependant increment of global myonuclear density (from 86 to 104 nuclei/mm in the absence and to 87 nuclei/mm in presence of CsA; Fig. 5a). Calcineurin inhibition strongly reduced the redistribution of myofibres towards the group with the highest myonuclear density (shift from 8% to 62% in the absence of CsA versus shift from 8% to 20% when CsA was co-administrated; Fig. 5b). Fig. 5Positive effects of PPARbeta on myonuclear density are calcineurin dependent. a Quantification of nuclei number in isolated DAPI-stained fibres harvested from tibialis anterior of 10-week-old C57Bl6 animals (n = 160, four animals per group, 40 fibres per animal), treated 2 days with vehicle (Ct), cyclosporine A (CsA), PPARbeta agonist GW0742 (2d) or PPARbeta agonist GW0742 and cyclosporine A (2d + CsA). *p < 0.01, different from Ct, CsA and 2d + CsA groups. b Distribution of myofibres population counted in a using the same classification as in Fig. 1b. Percentage of each group, mean number of nuclei in each group (Mean) and standard deviation (s.d.) are reported for each treatment
###end p 50
###begin p 51
###xml 78 79 75 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 208 209 205 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 293 295 290 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 314 317 311 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CsA</italic>
###xml 345 347 339 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2d</italic>
###xml 396 404 387 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2d&#8201;+&#8201;CsA</italic>
###xml 408 409 399 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 462 463 453 454 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 512 513 503 504 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 555 557 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1b</xref>
###xml 622 626 613 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mean</italic>
###xml 652 656 643 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">s.d.</italic>
Positive effects of PPARbeta on myonuclear density are calcineurin dependent. a Quantification of nuclei number in isolated DAPI-stained fibres harvested from tibialis anterior of 10-week-old C57Bl6 animals (n = 160, four animals per group, 40 fibres per animal), treated 2 days with vehicle (Ct), cyclosporine A (CsA), PPARbeta agonist GW0742 (2d) or PPARbeta agonist GW0742 and cyclosporine A (2d + CsA). *p < 0.01, different from Ct, CsA and 2d + CsA groups. b Distribution of myofibres population counted in a using the same classification as in Fig. 1b. Percentage of each group, mean number of nuclei in each group (Mean) and standard deviation (s.d.) are reported for each treatment
###end p 51
###begin p 52
###xml 131 132 131 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 393 394 393 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 486 487 486 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 631 637 628 634 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;6</label>
###xml 697 698 694 695 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 766 773 763 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DMSO 5H</italic>
###xml 867 868 864 865 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 979 986 976 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DMSO 5H</italic>
###xml 997 1002 994 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GW 5H</italic>
###xml 1034 1045 1031 1042 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CsA&#8201;+&#8201;GW 5H</italic>
###xml 1120 1121 1117 1118 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1173 1180 1170 1177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DMSO 5h</italic>
###xml 1182 1190 1179 1187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DMSO 24h</italic>
###xml 1232 1237 1229 1234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GW 5h</italic>
###xml 1239 1245 1236 1242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GW 24h</italic>
###xml 1247 1253 1244 1250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GW 48h</italic>
###xml 1311 1312 1308 1309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1324 1325 1321 1322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1363 1364 1360 1361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 637 1685 634 1674 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="53">GW0742 induces calcineurin A-dependent NFAT nuclearization. <bold>a</bold> Calcineurin and P85 Western blot analysis after control treatment (<italic>DMSO 5H</italic>) or different times of GW0742 treatment (2, 5, 8, and 24&#160;h). P85 is used as loading control. <bold>b</bold> Immunohistochemical localization of NFATc1 using cryosections of TLA muscles from mice treated 5&#160;h with DMSO (<italic>DMSO 5H</italic>), GW0742 (<italic>GW 5H</italic>) or cyclosporine A and GW0742 (<italic>CsA&#8201;+&#8201;GW 5H</italic>). Note the increased NFATc1 nuclearization only in GW 5H-treated animals. <bold>c</bold> TLA muscles from mice treated 5 or 24&#160;h with DMSO (<italic>DMSO 5h</italic>, <italic>DMSO 24h</italic>), or treated 5, 24, or 48&#160;h with GW0742 (<italic>GW 5h</italic>, <italic>GW 24h</italic>, <italic>GW 48h</italic>) were used for subcellular fractionation in cytoplasmic (<italic>C</italic>), nuclear (<italic>N</italic>) and insoluble-chromatin-associated (<italic>I</italic>) proteins and subsequent Western blot analysis. Note the increased nuclear localization of NFATc1 and NFATc3 in response to PPAR&#946; activation. CREB (nuclear), Rho GDI&#945; (cytoplasmic) and acetylated histone H3 (H3, Chromatin associated) antibodies were used to evaluate the purity of each fraction. Scale bar, 50&#160;&#956;m</p>
###xml 637 1685 634 1674 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="53">GW0742 induces calcineurin A-dependent NFAT nuclearization. <bold>a</bold> Calcineurin and P85 Western blot analysis after control treatment (<italic>DMSO 5H</italic>) or different times of GW0742 treatment (2, 5, 8, and 24&#160;h). P85 is used as loading control. <bold>b</bold> Immunohistochemical localization of NFATc1 using cryosections of TLA muscles from mice treated 5&#160;h with DMSO (<italic>DMSO 5H</italic>), GW0742 (<italic>GW 5H</italic>) or cyclosporine A and GW0742 (<italic>CsA&#8201;+&#8201;GW 5H</italic>). Note the increased NFATc1 nuclearization only in GW 5H-treated animals. <bold>c</bold> TLA muscles from mice treated 5 or 24&#160;h with DMSO (<italic>DMSO 5h</italic>, <italic>DMSO 24h</italic>), or treated 5, 24, or 48&#160;h with GW0742 (<italic>GW 5h</italic>, <italic>GW 24h</italic>, <italic>GW 48h</italic>) were used for subcellular fractionation in cytoplasmic (<italic>C</italic>), nuclear (<italic>N</italic>) and insoluble-chromatin-associated (<italic>I</italic>) proteins and subsequent Western blot analysis. Note the increased nuclear localization of NFATc1 and NFATc3 in response to PPAR&#946; activation. CREB (nuclear), Rho GDI&#945; (cytoplasmic) and acetylated histone H3 (H3, Chromatin associated) antibodies were used to evaluate the purity of each fraction. Scale bar, 50&#160;&#956;m</p></caption>
###xml 1685 1685 1674 1674 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="424_2009_676_Fig6_HTML" id="MO6"/>
###xml 631 1685 628 1674 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig6"><label>Fig.&#160;6</label><caption><p textid="53">GW0742 induces calcineurin A-dependent NFAT nuclearization. <bold>a</bold> Calcineurin and P85 Western blot analysis after control treatment (<italic>DMSO 5H</italic>) or different times of GW0742 treatment (2, 5, 8, and 24&#160;h). P85 is used as loading control. <bold>b</bold> Immunohistochemical localization of NFATc1 using cryosections of TLA muscles from mice treated 5&#160;h with DMSO (<italic>DMSO 5H</italic>), GW0742 (<italic>GW 5H</italic>) or cyclosporine A and GW0742 (<italic>CsA&#8201;+&#8201;GW 5H</italic>). Note the increased NFATc1 nuclearization only in GW 5H-treated animals. <bold>c</bold> TLA muscles from mice treated 5 or 24&#160;h with DMSO (<italic>DMSO 5h</italic>, <italic>DMSO 24h</italic>), or treated 5, 24, or 48&#160;h with GW0742 (<italic>GW 5h</italic>, <italic>GW 24h</italic>, <italic>GW 48h</italic>) were used for subcellular fractionation in cytoplasmic (<italic>C</italic>), nuclear (<italic>N</italic>) and insoluble-chromatin-associated (<italic>I</italic>) proteins and subsequent Western blot analysis. Note the increased nuclear localization of NFATc1 and NFATc3 in response to PPAR&#946; activation. CREB (nuclear), Rho GDI&#945; (cytoplasmic) and acetylated histone H3 (H3, Chromatin associated) antibodies were used to evaluate the purity of each fraction. Scale bar, 50&#160;&#956;m</p></caption><graphic position="anchor" xlink:href="424_2009_676_Fig6_HTML" id="MO6"/></fig>
###xml 951 955 <span type="species:ncbi:10090">mice</span>
###xml 1139 1143 <span type="species:ncbi:10090">mice</span>
Our data also indicated that in TLA muscle, GW0742 treatment did not promote an increase of calcineurin at the protein level (Fig. 6a) but rather provokes an induction of its phosphatase activity as attested by the rapid nuclear translocation of nuclear factor of activated T cells C1 and C3. Indeed, enhanced NFATc1 nuclearization can be evidenced as soon as 5 h after GW0742 treatment (Fig. 6b, c). It remained high at 24 h of treatment and returned to control value after 48 h (Fig. 6c). NFATc3 nuclearization can be evidenced after 24 h of PPARbeta agonist treatment, and it returned to control values after 48 h of treatment. Fig. 6GW0742 induces calcineurin A-dependent NFAT nuclearization. a Calcineurin and P85 Western blot analysis after control treatment (DMSO 5H) or different times of GW0742 treatment (2, 5, 8, and 24 h). P85 is used as loading control. b Immunohistochemical localization of NFATc1 using cryosections of TLA muscles from mice treated 5 h with DMSO (DMSO 5H), GW0742 (GW 5H) or cyclosporine A and GW0742 (CsA + GW 5H). Note the increased NFATc1 nuclearization only in GW 5H-treated animals. c TLA muscles from mice treated 5 or 24 h with DMSO (DMSO 5h, DMSO 24h), or treated 5, 24, or 48 h with GW0742 (GW 5h, GW 24h, GW 48h) were used for subcellular fractionation in cytoplasmic (C), nuclear (N) and insoluble-chromatin-associated (I) proteins and subsequent Western blot analysis. Note the increased nuclear localization of NFATc1 and NFATc3 in response to PPARbeta activation. CREB (nuclear), Rho GDIalpha (cytoplasmic) and acetylated histone H3 (H3, Chromatin associated) antibodies were used to evaluate the purity of each fraction. Scale bar, 50 mum
###end p 52
###begin p 53
###xml 60 61 60 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 129 136 129 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DMSO 5H</italic>
###xml 230 231 230 231 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 342 349 342 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DMSO 5H</italic>
###xml 360 365 360 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GW 5H</italic>
###xml 397 408 397 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CsA&#8201;+&#8201;GW 5H</italic>
###xml 483 484 483 484 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 536 543 536 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DMSO 5h</italic>
###xml 545 553 545 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DMSO 24h</italic>
###xml 595 600 595 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GW 5h</italic>
###xml 602 608 602 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GW 24h</italic>
###xml 610 616 610 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GW 48h</italic>
###xml 674 675 674 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 687 688 687 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 726 727 726 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 314 318 <span type="species:ncbi:10090">mice</span>
###xml 502 506 <span type="species:ncbi:10090">mice</span>
GW0742 induces calcineurin A-dependent NFAT nuclearization. a Calcineurin and P85 Western blot analysis after control treatment (DMSO 5H) or different times of GW0742 treatment (2, 5, 8, and 24 h). P85 is used as loading control. b Immunohistochemical localization of NFATc1 using cryosections of TLA muscles from mice treated 5 h with DMSO (DMSO 5H), GW0742 (GW 5H) or cyclosporine A and GW0742 (CsA + GW 5H). Note the increased NFATc1 nuclearization only in GW 5H-treated animals. c TLA muscles from mice treated 5 or 24 h with DMSO (DMSO 5h, DMSO 24h), or treated 5, 24, or 48 h with GW0742 (GW 5h, GW 24h, GW 48h) were used for subcellular fractionation in cytoplasmic (C), nuclear (N) and insoluble-chromatin-associated (I) proteins and subsequent Western blot analysis. Note the increased nuclear localization of NFATc1 and NFATc3 in response to PPARbeta activation. CREB (nuclear), Rho GDIalpha (cytoplasmic) and acetylated histone H3 (H3, Chromatin associated) antibodies were used to evaluate the purity of each fraction. Scale bar, 50 mum
###end p 53
###begin title 54
Ageing promotes a decrease in myonuclear density, while PPARbeta agonist treatment restores a juvenile phenotype
###end title 54
###begin p 55
###xml 54 55 54 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 57 58 57 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 330 331 324 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7</xref>
###xml 384 385 375 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 394 395 385 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 685 687 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 776 777 761 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 863 864 848 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 882 883 867 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 934 935 919 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7</xref>
###xml 1083 1084 1065 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1109 1110 1091 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1161 1162 1143 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7</xref>
###xml 1232 1238 1211 1217 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;7</label>
###xml 1302 1303 1278 1279 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1391 1400 1364 1373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">white bar</italic>
###xml 1420 1428 1393 1401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dark bar</italic>
###xml 1495 1516 1468 1489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec9" ref-type="sec">Materials and methods</xref>
###xml 1520 1521 1493 1494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1569 1581 1542 1554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pound sign p</italic>
###xml 1630 1631 1603 1604 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1733 1750 1703 1720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cross-hatched bar</italic>
###xml 1760 1768 1730 1738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dark bar</italic>
###xml 1856 1877 1826 1847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec9" ref-type="sec">Materials and methods</xref>
###xml 1881 1882 1851 1852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1952 1953 1922 1923 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1958 1959 1928 1929 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1238 2007 1217 1977 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="56">Ageing reduces expression of PPAR&#946;, catalase and PDK4 mRNAs. <bold>a</bold> Quantification of PPAR&#946;, catalase and PDK4 using mRNAs from muscles of 10-week-old (<italic>white bar</italic>) and 19-month-old (<italic>dark bar</italic>) mice (five animals per group) and qPCR analyses as described in &#8220;<xref rid="Sec9" ref-type="sec">Materials and methods</xref>&#8221;. *<italic>p</italic>&#8201;&lt;&#8201;0.05, different from 10-week-old mice group; <italic>pound sign p</italic>&#8201;&lt;&#8201;0.005, different from 10-week-old mice group. <bold>b</bold> Quantification of PPAR&#946;, catalase and PDK4 using mRNAs from muscles of 20-month-old mice treated (<italic>cross-hatched bar</italic>) or not (<italic>dark bar</italic>) during 4&#160;days with GW0742 (four animals per group) and qPCR analyses as described in &#8220;<xref rid="Sec9" ref-type="sec">Materials and methods</xref>&#8221;. *<italic>p</italic>&#8201;&lt;&#8201;0.05, different from 20-month-old untreated mice group. Results in <bold>a</bold> and <bold>b</bold> were normalised using 36B4 as housekeeping gene</p>
###xml 1238 2007 1217 1977 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="56">Ageing reduces expression of PPAR&#946;, catalase and PDK4 mRNAs. <bold>a</bold> Quantification of PPAR&#946;, catalase and PDK4 using mRNAs from muscles of 10-week-old (<italic>white bar</italic>) and 19-month-old (<italic>dark bar</italic>) mice (five animals per group) and qPCR analyses as described in &#8220;<xref rid="Sec9" ref-type="sec">Materials and methods</xref>&#8221;. *<italic>p</italic>&#8201;&lt;&#8201;0.05, different from 10-week-old mice group; <italic>pound sign p</italic>&#8201;&lt;&#8201;0.005, different from 10-week-old mice group. <bold>b</bold> Quantification of PPAR&#946;, catalase and PDK4 using mRNAs from muscles of 20-month-old mice treated (<italic>cross-hatched bar</italic>) or not (<italic>dark bar</italic>) during 4&#160;days with GW0742 (four animals per group) and qPCR analyses as described in &#8220;<xref rid="Sec9" ref-type="sec">Materials and methods</xref>&#8221;. *<italic>p</italic>&#8201;&lt;&#8201;0.05, different from 20-month-old untreated mice group. Results in <bold>a</bold> and <bold>b</bold> were normalised using 36B4 as housekeeping gene</p></caption>
###xml 2007 2007 1977 1977 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="424_2009_676_Fig7_HTML" id="MO7"/>
###xml 1232 2007 1211 1977 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig7"><label>Fig.&#160;7</label><caption><p textid="56">Ageing reduces expression of PPAR&#946;, catalase and PDK4 mRNAs. <bold>a</bold> Quantification of PPAR&#946;, catalase and PDK4 using mRNAs from muscles of 10-week-old (<italic>white bar</italic>) and 19-month-old (<italic>dark bar</italic>) mice (five animals per group) and qPCR analyses as described in &#8220;<xref rid="Sec9" ref-type="sec">Materials and methods</xref>&#8221;. *<italic>p</italic>&#8201;&lt;&#8201;0.05, different from 10-week-old mice group; <italic>pound sign p</italic>&#8201;&lt;&#8201;0.005, different from 10-week-old mice group. <bold>b</bold> Quantification of PPAR&#946;, catalase and PDK4 using mRNAs from muscles of 20-month-old mice treated (<italic>cross-hatched bar</italic>) or not (<italic>dark bar</italic>) during 4&#160;days with GW0742 (four animals per group) and qPCR analyses as described in &#8220;<xref rid="Sec9" ref-type="sec">Materials and methods</xref>&#8221;. *<italic>p</italic>&#8201;&lt;&#8201;0.05, different from 20-month-old untreated mice group. Results in <bold>a</bold> and <bold>b</bold> were normalised using 36B4 as housekeeping gene</p></caption><graphic position="anchor" xlink:href="424_2009_676_Fig7_HTML" id="MO7"/></fig>
###xml 248 253 <span type="species:ncbi:10090">mouse</span>
###xml 307 311 <span type="species:ncbi:10090">mice</span>
###xml 409 414 <span type="species:ncbi:10090">mouse</span>
###xml 446 451 <span type="species:ncbi:10090">mouse</span>
###xml 820 824 <span type="species:ncbi:10090">mice</span>
###xml 988 992 <span type="species:ncbi:10090">mice</span>
###xml 1430 1434 <span type="species:ncbi:10090">mice</span>
###xml 1557 1561 <span type="species:ncbi:10090">mice</span>
###xml 1618 1622 <span type="species:ncbi:10090">mice</span>
###xml 1719 1723 <span type="species:ncbi:10090">mice</span>
###xml 1929 1933 <span type="species:ncbi:10090">mice</span>
Myonuclear density is negatively regulated by ageing [4, 5]. In order to explore a possible role of PPARbeta in this a process, we first investigated the effect of ageing on PPARbeta expression by comparing the amounts of the corresponding mRNA in mouse TLA from adult (10-week-old) and aged (19-month-old) mice. As shown in Fig. 7, PPARbeta mRNA was down-regulated by more than 30% (p = 0.03, n = 5) in aged mouse muscles when compared to young mouse muscles. To check whether the decreased expression of PPARbeta impacts on gene regulation, we also quantified mRNA for two PPARbeta-target genes, namely catalase, that plays a crucial role in the protection against oxidative stress [23], and pyruvate dehydrogenase kinase 4 (PDK4) that is involved in metabolic regulations [7]. These experiments revealed that in aged mice, both genes were down-regulated (40%, p = 0.01, and 75%, p = 0.001 for catalase and PDK4, respectively; Fig. 7a). However, PPARbeta pathway remains active in aged mice as 4 days of GW0742 treatment promoted an up-regulation of these target genes (1.76-fold, p = 0.034, and 6.19-fold, p = 0.047 for catalase and PDK4, respectively; Fig. 7b). As expected, GW0742 treatment did not modify PPARbeta expression. Fig. 7Ageing reduces expression of PPARbeta, catalase and PDK4 mRNAs. a Quantification of PPARbeta, catalase and PDK4 using mRNAs from muscles of 10-week-old (white bar) and 19-month-old (dark bar) mice (five animals per group) and qPCR analyses as described in "Materials and methods". *p < 0.05, different from 10-week-old mice group; pound sign p < 0.005, different from 10-week-old mice group. b Quantification of PPARbeta, catalase and PDK4 using mRNAs from muscles of 20-month-old mice treated (cross-hatched bar) or not (dark bar) during 4 days with GW0742 (four animals per group) and qPCR analyses as described in "Materials and methods". *p < 0.05, different from 20-month-old untreated mice group. Results in a and b were normalised using 36B4 as housekeeping gene
###end p 55
###begin p 56
###xml 64 65 61 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 153 162 147 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">white bar</italic>
###xml 182 190 176 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dark bar</italic>
###xml 257 278 251 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec9" ref-type="sec">Materials and methods</xref>
###xml 282 283 276 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 331 343 325 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pound sign p</italic>
###xml 392 393 386 387 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 495 512 486 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cross-hatched bar</italic>
###xml 522 530 513 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dark bar</italic>
###xml 618 639 609 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec9" ref-type="sec">Materials and methods</xref>
###xml 643 644 634 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 714 715 705 706 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 720 721 711 712 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 192 196 <span type="species:ncbi:10090">mice</span>
###xml 319 323 <span type="species:ncbi:10090">mice</span>
###xml 380 384 <span type="species:ncbi:10090">mice</span>
###xml 481 485 <span type="species:ncbi:10090">mice</span>
###xml 691 695 <span type="species:ncbi:10090">mice</span>
Ageing reduces expression of PPARbeta, catalase and PDK4 mRNAs. a Quantification of PPARbeta, catalase and PDK4 using mRNAs from muscles of 10-week-old (white bar) and 19-month-old (dark bar) mice (five animals per group) and qPCR analyses as described in "Materials and methods". *p < 0.05, different from 10-week-old mice group; pound sign p < 0.005, different from 10-week-old mice group. b Quantification of PPARbeta, catalase and PDK4 using mRNAs from muscles of 20-month-old mice treated (cross-hatched bar) or not (dark bar) during 4 days with GW0742 (four animals per group) and qPCR analyses as described in "Materials and methods". *p < 0.05, different from 20-month-old untreated mice group. Results in a and b were normalised using 36B4 as housekeeping gene
###end p 56
###begin p 57
###xml 139 140 139 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 164 165 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 204 205 204 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 327 328 327 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 527 528 527 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 610 611 610 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 627 628 627 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 727 728 727 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 767 768 767 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 889 890 889 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 894 900 894 900 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;8</label>
###xml 1017 1018 1014 1015 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1132 1134 1129 1131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 1136 1138 1133 1135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tg</italic>
###xml 1140 1142 1137 1139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GW</italic>
###xml 1162 1166 1159 1163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">19Ct</italic>
###xml 1168 1172 1165 1169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">19Tg</italic>
###xml 1174 1178 1171 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">19GW</italic>
###xml 1191 1192 1188 1189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1291 1293 1288 1290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 1295 1299 1292 1296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">19Ct</italic>
###xml 1340 1342 1334 1336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tg</italic>
###xml 1344 1348 1338 1342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">19Tg</italic>
###xml 1385 1387 1379 1381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GW</italic>
###xml 1389 1393 1383 1387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">19GW</italic>
###xml 1397 1398 1391 1392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1447 1449 1441 1443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 1451 1453 1445 1447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tg</italic>
###xml 1455 1457 1449 1451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GW</italic>
###xml 1460 1472 1454 1466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pound sign p</italic>
###xml 1520 1522 1514 1516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 1524 1528 1518 1522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">19Ct</italic>
###xml 1531 1532 1525 1526 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1581 1582 1575 1576 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1624 1626 1618 1620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1b</xref>
###xml 1691 1695 1685 1689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mean</italic>
###xml 1721 1725 1715 1719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">s.d.</italic>
###xml 900 1771 900 1765 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="58">Ageing promotes a 5% decrease of myonuclear density, while PPAR&#946; agonist treatment restores a juvenile phenotype. <bold>a</bold> Quantification of nuclei number in isolated DAPI-stained fibres harvested from tibialis anterior of 10-week-old (<italic>Ct</italic>, <italic>Tg</italic>, <italic>GW</italic>) and 19-month-old (<italic>19Ct</italic>, <italic>19Tg</italic>, <italic>19GW</italic>) B6D2 mice (<italic>n</italic>&#8201;=&#8201;160, four animals per group, 40 fibres per animal). Mice were either treated with vehicle only (<italic>Ct</italic>, <italic>19Ct</italic>) or untreated PPAR&#946; transgenic mice (<italic>Tg</italic>, <italic>19Tg</italic>) or treated for 4&#160;days with GW0742 (<italic>GW</italic>, <italic>19GW</italic>). *<italic>p</italic>&#8201;&lt;&#8201;0.01, different from 10-week-old mice groups (<italic>Ct</italic>, <italic>Tg</italic>, <italic>GW</italic>); <italic>pound sign p</italic>&#8201;&lt;&#8201;0.05, different from vehicle-treated groups (<italic>Ct</italic>, <italic>19Ct</italic>). <bold>b</bold> Distribution of myofibres population counted in <bold>a</bold> using the same classification as in Fig.&#160;<xref rid="Fig1" ref-type="fig">1b</xref>. Percentage of each group, mean number of nuclei in each group (<italic>Mean</italic>) and standard deviation (<italic>s.d.</italic>) are reported for each experimental condition</p>
###xml 900 1771 900 1765 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="58">Ageing promotes a 5% decrease of myonuclear density, while PPAR&#946; agonist treatment restores a juvenile phenotype. <bold>a</bold> Quantification of nuclei number in isolated DAPI-stained fibres harvested from tibialis anterior of 10-week-old (<italic>Ct</italic>, <italic>Tg</italic>, <italic>GW</italic>) and 19-month-old (<italic>19Ct</italic>, <italic>19Tg</italic>, <italic>19GW</italic>) B6D2 mice (<italic>n</italic>&#8201;=&#8201;160, four animals per group, 40 fibres per animal). Mice were either treated with vehicle only (<italic>Ct</italic>, <italic>19Ct</italic>) or untreated PPAR&#946; transgenic mice (<italic>Tg</italic>, <italic>19Tg</italic>) or treated for 4&#160;days with GW0742 (<italic>GW</italic>, <italic>19GW</italic>). *<italic>p</italic>&#8201;&lt;&#8201;0.01, different from 10-week-old mice groups (<italic>Ct</italic>, <italic>Tg</italic>, <italic>GW</italic>); <italic>pound sign p</italic>&#8201;&lt;&#8201;0.05, different from vehicle-treated groups (<italic>Ct</italic>, <italic>19Ct</italic>). <bold>b</bold> Distribution of myofibres population counted in <bold>a</bold> using the same classification as in Fig.&#160;<xref rid="Fig1" ref-type="fig">1b</xref>. Percentage of each group, mean number of nuclei in each group (<italic>Mean</italic>) and standard deviation (<italic>s.d.</italic>) are reported for each experimental condition</p></caption>
###xml 1771 1771 1765 1765 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="424_2009_676_Fig8_HTML" id="MO8"/>
###xml 894 1771 894 1765 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig8"><label>Fig.&#160;8</label><caption><p textid="58">Ageing promotes a 5% decrease of myonuclear density, while PPAR&#946; agonist treatment restores a juvenile phenotype. <bold>a</bold> Quantification of nuclei number in isolated DAPI-stained fibres harvested from tibialis anterior of 10-week-old (<italic>Ct</italic>, <italic>Tg</italic>, <italic>GW</italic>) and 19-month-old (<italic>19Ct</italic>, <italic>19Tg</italic>, <italic>19GW</italic>) B6D2 mice (<italic>n</italic>&#8201;=&#8201;160, four animals per group, 40 fibres per animal). Mice were either treated with vehicle only (<italic>Ct</italic>, <italic>19Ct</italic>) or untreated PPAR&#946; transgenic mice (<italic>Tg</italic>, <italic>19Tg</italic>) or treated for 4&#160;days with GW0742 (<italic>GW</italic>, <italic>19GW</italic>). *<italic>p</italic>&#8201;&lt;&#8201;0.01, different from 10-week-old mice groups (<italic>Ct</italic>, <italic>Tg</italic>, <italic>GW</italic>); <italic>pound sign p</italic>&#8201;&lt;&#8201;0.05, different from vehicle-treated groups (<italic>Ct</italic>, <italic>19Ct</italic>). <bold>b</bold> Distribution of myofibres population counted in <bold>a</bold> using the same classification as in Fig.&#160;<xref rid="Fig1" ref-type="fig">1b</xref>. Percentage of each group, mean number of nuclei in each group (<italic>Mean</italic>) and standard deviation (<italic>s.d.</italic>) are reported for each experimental condition</p></caption><graphic position="anchor" xlink:href="424_2009_676_Fig8_HTML" id="MO8"/></fig>
###xml 113 117 <span type="species:ncbi:10090">mice</span>
###xml 279 283 <span type="species:ncbi:10090">mice</span>
###xml 493 497 <span type="species:ncbi:10090">mice</span>
###xml 716 720 <span type="species:ncbi:10090">mice</span>
###xml 1185 1189 <span type="species:ncbi:10090">mice</span>
###xml 1247 1251 <span type="species:ncbi:10090">Mice</span>
###xml 1323 1338 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1434 1438 <span type="species:ncbi:10090">mice</span>
The effect of ageing on myonuclear density was next investigated in TLA muscles from young and aged B6D2 control mice (Ct and 19Ct in Fig. 8a, b). As shown in Fig. 8a and in agreement with other reports [5], global myonuclear density was slightly but significantly lower in aged mice when compared to young adult animals (-5%, p = 0.0057). The effect of ageing on myonuclear density is further evidenced when evaluating the fibre distribution profile in the previously defined groups. In aged mice, the number of fibres in the F < 85 group was increased by 1.35-fold (31% to 42%), whereas the fibre numbers in F > 100 and 85 < F < 100 groups were reduced 1.22- and 1.17-fold, respectively compared to those of young mice (Fig. 8b). Furthermore, the mean value in the F < 85 group seems to be lower in aged animals than in young adult animals, whereas other mean values remain stable (Fig. 8b). Fig. 8Ageing promotes a 5% decrease of myonuclear density, while PPARbeta agonist treatment restores a juvenile phenotype. a Quantification of nuclei number in isolated DAPI-stained fibres harvested from tibialis anterior of 10-week-old (Ct, Tg, GW) and 19-month-old (19Ct, 19Tg, 19GW) B6D2 mice (n = 160, four animals per group, 40 fibres per animal). Mice were either treated with vehicle only (Ct, 19Ct) or untreated PPARbeta transgenic mice (Tg, 19Tg) or treated for 4 days with GW0742 (GW, 19GW). *p < 0.01, different from 10-week-old mice groups (Ct, Tg, GW); pound sign p < 0.05, different from vehicle-treated groups (Ct, 19Ct). b Distribution of myofibres population counted in a using the same classification as in Fig. 1b. Percentage of each group, mean number of nuclei in each group (Mean) and standard deviation (s.d.) are reported for each experimental condition
###end p 57
###begin p 58
###xml 117 118 114 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 232 234 229 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 236 238 233 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tg</italic>
###xml 240 242 237 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GW</italic>
###xml 262 266 259 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">19Ct</italic>
###xml 268 272 265 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">19Tg</italic>
###xml 274 278 271 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">19GW</italic>
###xml 291 292 288 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 391 393 388 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 395 399 392 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">19Ct</italic>
###xml 440 442 434 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tg</italic>
###xml 444 448 438 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">19Tg</italic>
###xml 485 487 479 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GW</italic>
###xml 489 493 483 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">19GW</italic>
###xml 497 498 491 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 547 549 541 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 551 553 545 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tg</italic>
###xml 555 557 549 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GW</italic>
###xml 560 572 554 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pound sign p</italic>
###xml 620 622 614 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 624 628 618 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">19Ct</italic>
###xml 631 632 625 626 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 681 682 675 676 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 724 726 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1b</xref>
###xml 791 795 785 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mean</italic>
###xml 821 825 815 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">s.d.</italic>
###xml 285 289 <span type="species:ncbi:10090">mice</span>
###xml 347 351 <span type="species:ncbi:10090">Mice</span>
###xml 423 438 <span type="species:ncbi:10090">transgenic mice</span>
###xml 534 538 <span type="species:ncbi:10090">mice</span>
Ageing promotes a 5% decrease of myonuclear density, while PPARbeta agonist treatment restores a juvenile phenotype. a Quantification of nuclei number in isolated DAPI-stained fibres harvested from tibialis anterior of 10-week-old (Ct, Tg, GW) and 19-month-old (19Ct, 19Tg, 19GW) B6D2 mice (n = 160, four animals per group, 40 fibres per animal). Mice were either treated with vehicle only (Ct, 19Ct) or untreated PPARbeta transgenic mice (Tg, 19Tg) or treated for 4 days with GW0742 (GW, 19GW). *p < 0.01, different from 10-week-old mice groups (Ct, Tg, GW); pound sign p < 0.05, different from vehicle-treated groups (Ct, 19Ct). b Distribution of myofibres population counted in a using the same classification as in Fig. 1b. Percentage of each group, mean number of nuclei in each group (Mean) and standard deviation (s.d.) are reported for each experimental condition
###end p 58
###begin p 59
###xml 328 329 319 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 414 415 405 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 645 646 636 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 695 696 686 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 796 797 787 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 853 854 844 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 1001 1002 989 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 1091 1092 1079 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1141 1142 1129 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 1191 1192 1179 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1223 1224 1211 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 1349 1350 1334 1335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 1441 1442 1426 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1553 1554 1535 1536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1631 1632 1613 1614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 1728 1729 1710 1711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1754 1755 1736 1737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 1791 1792 1773 1774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1847 1848 1829 1830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1883 1884 1865 1866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 2031 2032 2013 2014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 2085 2086 2067 2068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 524 539 <span type="species:ncbi:10090">transgenic mice</span>
###xml 611 615 <span type="species:ncbi:10090">mice</span>
###xml 975 979 <span type="species:ncbi:10090">mice</span>
###xml 1026 1030 <span type="species:ncbi:10090">mice</span>
###xml 1302 1317 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1430 1434 <span type="species:ncbi:10090">mice</span>
###xml 1476 1480 <span type="species:ncbi:10090">mice</span>
###xml 1926 1930 <span type="species:ncbi:10090">mice</span>
###xml 1997 2001 <span type="species:ncbi:10090">mice</span>
To explore a possible beneficial action of PPARbeta pathway activation on myonuclear density, we next investigated the effects of muscle specific PPARbeta over-expression on the ageing-related loss of myonuclei. In elderly PPARbeta transgenic animals, we have observed a significant reduction in global myonuclear density (-7%, p < 0.0052) and a shift towards fibres that contain fewer nuclei (Tg and 19Tg in Fig. 8a, b) when compared to their younger counterparts. Despite this reduction, global myonuclear density in aged transgenic mice remained in the same order of value than that found in young untreated mice (compare CT and 19Tg in Fig. 8a). Furthermore, the percentage of fibres in the F > 100 group remained significantly higher in old transgenic animals than in control young animals (F > 100 = 28% and 46% in CT and 19Tg, respectively. Fig. 8b). Finally, we studied the effects of pharmacological PPARbeta activation on myonuclear density in young and old B6D2F1 mice (GW and 19GW in Fig. 8a, b). In young control mice, 4 days treatment with GW0742 resulted in an increase (14%, p = 0.048) in the global myonuclear density (Fig. 8a) and redistribution of fibres in favour of the F > 100 group (28% to 67%, Fig. 8b). This augmentation is similar to that observed in PPARbeta-over-expressing transgenic mice (compare CT, TG and GW in Fig. 8a) but is less important than the observed 20% increase in young C57Bl6-treated mice (Fig. 2a). Interestingly, in aged B6D2F1 mice (19GW), 4 days administration of PPARbeta agonist led not only to a 9% (p = 0.0318) increase in the myonuclear density (compare 19Ct and 19GW in Fig. 8a) but also to a redistribution of fibres in the group which contained more than 100 nuclei/mm (F > 100; 23% to 38%; Fig. 8b). The percentage of fibres in the F < 85 group was reduced (42% to 25%), whereas the 85 < F < 100 group remained stable (Fig. 8b). Interestingly, treatment allowed aged mice to reach similar global myonuclear density as 10-week-old control mice (compare 19GW and Ct in Fig. 8a), almost the same fibre distribution profile (Fig. 8b) and slightly better mean values in the three groups, indicating that PPARbeta activation could compensate the age-related loss of myonuclei.
###end p 59
###begin title 60
Ageing promotes a decrease in oxidative myofibre number, while PPARbeta agonist treatment restores a juvenile phenotype
###end title 60
###begin p 61
###xml 421 423 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 671 672 668 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1050 1051 1047 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1455 1456 1446 1447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1466 1467 1457 1458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1526 1527 1517 1518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1535 1536 1526 1527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1619 1621 1607 1609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1624 1631 1612 1619 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 1631 1755 1619 1740 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="62">Ageing promotes a decrease of TLA oxidative fibre proportion, while PPAR&#946; agonist treatment restores a juvenile phenotype</p>
###xml 1631 1755 1619 1740 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="62">Ageing promotes a decrease of TLA oxidative fibre proportion, while PPAR&#946; agonist treatment restores a juvenile phenotype</p></caption>
###xml 1755 1767 1740 1752 <th xmlns:xlink="http://www.w3.org/1999/xlink">Age in month</th>
###xml 1767 1777 1752 1762 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">2.5 months</th>
###xml 1777 1786 1762 1771 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">22 months</th>
###xml 1755 1786 1740 1771 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Age in month</th><th colspan="3">2.5 months</th><th colspan="3">22 months</th></tr>
###xml 1786 1797 1771 1782 <th xmlns:xlink="http://www.w3.org/1999/xlink">C57Bl6 Mice</th>
###xml 1797 1804 1782 1789 <th xmlns:xlink="http://www.w3.org/1999/xlink">Control</th>
###xml 1804 1809 1789 1794 <th xmlns:xlink="http://www.w3.org/1999/xlink">GW96h</th>
###xml 1809 1810 1794 1795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1809 1816 1794 1801 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value</th>
###xml 1816 1823 1801 1808 <th xmlns:xlink="http://www.w3.org/1999/xlink">Control</th>
###xml 1823 1828 1808 1813 <th xmlns:xlink="http://www.w3.org/1999/xlink">GW96h</th>
###xml 1828 1829 1813 1814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1828 1835 1813 1820 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value</th>
###xml 1786 1835 1771 1820 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>C57Bl6 Mice</th><th>Control</th><th>GW96h</th><th><italic>p</italic> value</th><th>Control</th><th>GW96h</th><th><italic>p</italic> value</th></tr>
###xml 1755 1835 1740 1820 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Age in month</th><th colspan="3">2.5 months</th><th colspan="3">22 months</th></tr><tr><th>C57Bl6 Mice</th><th>Control</th><th>GW96h</th><th><italic>p</italic> value</th><th>Control</th><th>GW96h</th><th><italic>p</italic> value</th></tr></thead>
###xml 1835 1851 1820 1836 <td xmlns:xlink="http://www.w3.org/1999/xlink">SDH positive (%)</td>
###xml 1851 1863 1836 1846 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">46.4&#8201;&#177;&#8201;1.3</td>
###xml 1863 1875 1846 1856 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">54.6&#8201;&#177;&#8201;1.9</td>
###xml 1875 1882 1856 1863 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2212;" align="char">1.5E&#8722;05</td>
###xml 1882 1894 1863 1873 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">39.3&#8201;&#177;&#8201;1.4</td>
###xml 1894 1906 1873 1883 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">47.6&#8201;&#177;&#8201;2.4</td>
###xml 1906 1912 1883 1889 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0067</td>
###xml 1835 1912 1820 1889 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>SDH positive (%)</td><td char="&#177;" align="char">46.4&#8201;&#177;&#8201;1.3</td><td char="&#177;" align="char">54.6&#8201;&#177;&#8201;1.9</td><td char="&#8722;" align="char">1.5E&#8722;05</td><td char="&#177;" align="char">39.3&#8201;&#177;&#8201;1.4</td><td char="&#177;" align="char">47.6&#8201;&#177;&#8201;2.4</td><td char="." align="char">0.0067</td></tr>
###xml 1912 1928 1889 1905 <td xmlns:xlink="http://www.w3.org/1999/xlink">SDH negative (%)</td>
###xml 1928 1940 1905 1915 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">53.6&#8201;&#177;&#8201;1.3</td>
###xml 1940 1952 1915 1925 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">45.4&#8201;&#177;&#8201;1.9</td>
###xml 1952 1959 1925 1932 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2212;" align="char">1.5E&#8722;05</td>
###xml 1959 1971 1932 1942 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">60.7&#8201;&#177;&#8201;1.4</td>
###xml 1971 1983 1942 1952 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">52.4&#8201;&#177;&#8201;2.4</td>
###xml 1983 1989 1952 1958 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0067</td>
###xml 1912 1989 1889 1958 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>SDH negative (%)</td><td char="&#177;" align="char">53.6&#8201;&#177;&#8201;1.3</td><td char="&#177;" align="char">45.4&#8201;&#177;&#8201;1.9</td><td char="&#8722;" align="char">1.5E&#8722;05</td><td char="&#177;" align="char">60.7&#8201;&#177;&#8201;1.4</td><td char="&#177;" align="char">52.4&#8201;&#177;&#8201;2.4</td><td char="." align="char">0.0067</td></tr>
###xml 1835 1989 1820 1958 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>SDH positive (%)</td><td char="&#177;" align="char">46.4&#8201;&#177;&#8201;1.3</td><td char="&#177;" align="char">54.6&#8201;&#177;&#8201;1.9</td><td char="&#8722;" align="char">1.5E&#8722;05</td><td char="&#177;" align="char">39.3&#8201;&#177;&#8201;1.4</td><td char="&#177;" align="char">47.6&#8201;&#177;&#8201;2.4</td><td char="." align="char">0.0067</td></tr><tr><td>SDH negative (%)</td><td char="&#177;" align="char">53.6&#8201;&#177;&#8201;1.3</td><td char="&#177;" align="char">45.4&#8201;&#177;&#8201;1.9</td><td char="&#8722;" align="char">1.5E&#8722;05</td><td char="&#177;" align="char">60.7&#8201;&#177;&#8201;1.4</td><td char="&#177;" align="char">52.4&#8201;&#177;&#8201;2.4</td><td char="." align="char">0.0067</td></tr></tbody>
###xml 1755 1989 1740 1958 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Age in month</th><th colspan="3">2.5 months</th><th colspan="3">22 months</th></tr><tr><th>C57Bl6 Mice</th><th>Control</th><th>GW96h</th><th><italic>p</italic> value</th><th>Control</th><th>GW96h</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>SDH positive (%)</td><td char="&#177;" align="char">46.4&#8201;&#177;&#8201;1.3</td><td char="&#177;" align="char">54.6&#8201;&#177;&#8201;1.9</td><td char="&#8722;" align="char">1.5E&#8722;05</td><td char="&#177;" align="char">39.3&#8201;&#177;&#8201;1.4</td><td char="&#177;" align="char">47.6&#8201;&#177;&#8201;2.4</td><td char="." align="char">0.0067</td></tr><tr><td>SDH negative (%)</td><td char="&#177;" align="char">53.6&#8201;&#177;&#8201;1.3</td><td char="&#177;" align="char">45.4&#8201;&#177;&#8201;1.9</td><td char="&#8722;" align="char">1.5E&#8722;05</td><td char="&#177;" align="char">60.7&#8201;&#177;&#8201;1.4</td><td char="&#177;" align="char">52.4&#8201;&#177;&#8201;2.4</td><td char="." align="char">0.0067</td></tr></tbody></table>
###xml 1989 2180 1958 2149 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="63">In situ staining of succinate dehydrogenase activity using cross-sections around mid-portion of the TLA muscles from 10-week-old and 22-month-old animals treated or not for 4&#160;days with GW0742</p>
###xml 1989 2180 1958 2149 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="63">In situ staining of succinate dehydrogenase activity using cross-sections around mid-portion of the TLA muscles from 10-week-old and 22-month-old animals treated or not for 4&#160;days with GW0742</p></table-wrap-foot>
###xml 1624 2180 1612 2149 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="62">Ageing promotes a decrease of TLA oxidative fibre proportion, while PPAR&#946; agonist treatment restores a juvenile phenotype</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Age in month</th><th colspan="3">2.5 months</th><th colspan="3">22 months</th></tr><tr><th>C57Bl6 Mice</th><th>Control</th><th>GW96h</th><th><italic>p</italic> value</th><th>Control</th><th>GW96h</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>SDH positive (%)</td><td char="&#177;" align="char">46.4&#8201;&#177;&#8201;1.3</td><td char="&#177;" align="char">54.6&#8201;&#177;&#8201;1.9</td><td char="&#8722;" align="char">1.5E&#8722;05</td><td char="&#177;" align="char">39.3&#8201;&#177;&#8201;1.4</td><td char="&#177;" align="char">47.6&#8201;&#177;&#8201;2.4</td><td char="." align="char">0.0067</td></tr><tr><td>SDH negative (%)</td><td char="&#177;" align="char">53.6&#8201;&#177;&#8201;1.3</td><td char="&#177;" align="char">45.4&#8201;&#177;&#8201;1.9</td><td char="&#8722;" align="char">1.5E&#8722;05</td><td char="&#177;" align="char">60.7&#8201;&#177;&#8201;1.4</td><td char="&#177;" align="char">52.4&#8201;&#177;&#8201;2.4</td><td char="." align="char">0.0067</td></tr></tbody></table><table-wrap-foot><p textid="63">In situ staining of succinate dehydrogenase activity using cross-sections around mid-portion of the TLA muscles from 10-week-old and 22-month-old animals treated or not for 4&#160;days with GW0742</p></table-wrap-foot></table-wrap>
###xml 454 458 <span type="species:ncbi:10090">mice</span>
###xml 940 945 <span type="species:ncbi:10090">mouse</span>
To characterise the impact of ageing on fibre type composition and the effects of PPARbeta activation on this parameter, we used cross-sections around mid-portion of the TLA muscles from 10-week-old and 22-month-old animals treated or not for 4 days with GW0742 for in situ staining of succinate dehydrogenase activity, which is a marker of mitochondrial complex II content. In accordance with our previous observations [10], TLA from young adult C57Bl6 mice contains about 46% of SDH-positive fibres and 54% of SDH-negative fibres, and GW0742 treatment promotes an increment of the oxidative phenotype characterised by increased proportion of SDH-positive fibres (Table 1). TLA from aged animals displayed a less oxidative phenotype with decreased proportion of SDH-positive fibres (39.3 % in aged versus 46.3% in young animals). Interestingly, 4 days of GW0742 administration promoted an increase of SDH-positive fibre proportion in aged mouse TLA, resulting in a phenotype that is nearly similar to that observed in young untreated animals (Table 1). This PPARbeta-promoted increment of oxidative capabilities of TLA from aged animals was then confirmed by the determination of citrate synthase (CS) activity as a marker of the oxidative metabolism and lactate dehydrogenase (LDH) activity as a marker of glycolytic metabolism. These experiments showed that, after 4 days of PPARbeta agonist treatment, the CS specific activity was increased by 16.7% (p = 0.002, n = 4), while the LDH-specific activity remained unchanged (p > 0.5, n = 4). Comparable effects were previously reported in PPARbeta transgenic animals [18]. Table 1Ageing promotes a decrease of TLA oxidative fibre proportion, while PPARbeta agonist treatment restores a juvenile phenotypeAge in month2.5 months22 monthsC57Bl6 MiceControlGW96hp valueControlGW96hp valueSDH positive (%)46.4 +/- 1.354.6 +/- 1.91.5E-0539.3 +/- 1.447.6 +/- 2.40.0067SDH negative (%)53.6 +/- 1.345.4 +/- 1.91.5E-0560.7 +/- 1.452.4 +/- 2.40.0067In situ staining of succinate dehydrogenase activity using cross-sections around mid-portion of the TLA muscles from 10-week-old and 22-month-old animals treated or not for 4 days with GW0742
###end p 61
###begin p 62
Ageing promotes a decrease of TLA oxidative fibre proportion, while PPARbeta agonist treatment restores a juvenile phenotype
###end p 62
###begin p 63
In situ staining of succinate dehydrogenase activity using cross-sections around mid-portion of the TLA muscles from 10-week-old and 22-month-old animals treated or not for 4 days with GW0742
###end p 63
###begin title 64
Discussion
###end title 64
###begin p 65
###xml 146 148 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 150 152 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 70 74 <span type="species:ncbi:10090">mice</span>
###xml 203 218 <span type="species:ncbi:10090">transgenic mice</span>
###xml 248 252 <span type="species:ncbi:10090">mice</span>
We previously reported that PPARbeta activation or over-expression in mice induces striking skeletal muscle oxidative and angiogenic remodelling [10, 18]. We report here a new phenotype in both PPARbeta transgenic mice and PPARbeta agonist-treated mice, consisting in massive activation, recruitment and fusion of MPCs to both pre-existing and newly formed myofibres. Fusion of such a large number of myonuclei may represent a key event in the PPARbeta-promoted oxidative muscle remodelling.
###end p 65
###begin p 66
###xml 549 551 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 1094 1095 1079 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1244 1246 1226 1228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 1354 1355 1336 1337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1367 1368 1349 1350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1376 1377 1358 1359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1620 1621 1596 1597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1627 1628 1603 1604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1866 1867 1842 1843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1882 1883 1858 1859 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 2019 2020 1995 1996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 347 351 <span type="species:ncbi:10090">mice</span>
This newly described PPARbeta-promoted phenotype is remarkable in magnitude and quickness. First, in B6D2F1 mice, muscle-specific PPARbeta over-expression or pharmacological activation induced a 14% increase in myonuclear density when compared to control animals. This myonuclear density increment is even more pronounced in GW0742-treated C57Bl6 mice which display a 20% augmentation. Taking into account that in the TLA of C57Bl6, PPARbeta agonist treatment also leads to a muscle hyperplasia corresponding to the generation of 600 new myofibres [10], it can be estimated that PPARbeta activation resulted in addition of about one million of new myonuclei to each muscle. Furthermore, these events of MPC activation, recruitment and fusion could also happen in other muscles, resulting in addition of several millions of new myonuclei per animal. The quickness of myonuclear accretion after PPARbeta administration is also very impressive. In both C57Bl6 and B6D2F1, GW0742 treatment promoted an increase in myonuclear density that was already detectable at day 1 and achieved at day 2 (Fig. 2). This process takes place in the same time frame that we have already determined for the PPARbeta-promoted myogenic/angiogenic muscle remodelling [10]. Analysis of the fibre distribution depending on their myonuclear content per millimetre of fibre length (F < 85; 85 < F < 100; F > 100) allowed a better description of the effects of PPARbeta pathway activation. Both PPARbeta over-expression and its pharmacological activation highly increased the number of fibres that contain more than 100 nuclei/mm fibre length (Fig. 1b and 2b). Furthermore, in GW0742-treated animals, we observed a time-dependent shift from the two classes of low myonuclear density fibres towards high myonuclear density fibres. Indeed, in C57Bl6, the fibres that contain less than 100 nuclei (F < 85 and 85 < F < 100) represent 93% of the myofibres before the treatment, 66% after 1 day of treatment, and only 38% after 2 days of treatment (Fig. 2b). Since these fibres did not disappear, the most probable scenario is a rapid and progressive recruitment and fusion of MPCs to pre-existing and newly formed fibres.
###end p 66
###begin p 67
###xml 161 162 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 167 168 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 423 425 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 427 429 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 960 961 951 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 963 965 954 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 967 969 958 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 971 973 962 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
Another remarkable feature of the PPARbeta-promoted myonuclear accretion is the finding that proliferation of MPCs is not required for such a remodelling (Figs. 3 and 4). This is in contrast with other pathological or physiological situations leading to muscle remodelling, such as adaptation to exercise, overload or muscle regeneration, in which a critical and obligatory step of MPCs proliferation has been established [16, 26]. However, it should be noted that in these situations, muscle remodelling takes place within weeks and often follows muscle damage, whereas PPARbeta-promoted muscle remodelling is achieved in 2 days without any histological sign of fibre deterioration. All our observations argue in favour of a model, in which the PPARbeta pathway activates a pool of MPCs that are "committed" to differentiate and able to fuse to fibres omitting the obligate step of proliferation. Existence of such cells has already been suggested by others [1, 11, 24, 43].
###end p 67
###begin p 68
###xml 183 184 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 258 259 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 485 487 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 736 737 730 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 852 853 843 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 939 940 930 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 566 570 <span type="species:ncbi:10090">mice</span>
The central role of the calcineurin/NFAT pathway in the maintenance of fibre type composition and in muscle adaptation to physical exercise has been well documented (for review, see [3]). The calcineurin pathway has also been associated with MPC activation [8, 22, 34]. As cyclosporine A administration abolished both myogenic and angiogenic responses to PPARbeta activation, we previously proposed that active calcineurin pathway is required for PPARbeta-promoted muscle remodelling [10]. Data presented here reinforce this model as demonstrating that treatment of mice with GW0742 did not affect calcineurin A expression but induced calcineurin A activation as shown by the rapid nuclearization of both NFATc1 and NFATc3 in TLA (Fig. 6). The finding that CsA administration impaired the PPARbeta-dependent increase in global myonuclear density (Fig. 5a) as well as the redistribution of myofibres in the three defined fibre groups (Fig. 5b) strongly suggests that the calcineurin/NFAT pathway is involved directly in the PPARbeta-promoted myonuclear accretion. Further work is required to fully characterise the signalling cascade that follows PPARbeta-promoted NFAT activation.
###end p 68
###begin p 69
###xml 74 75 74 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 77 78 77 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 331 332 331 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 426 427 426 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 504 505 501 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7</xref>
###xml 600 602 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 604 606 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 640 641 634 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 646 647 640 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 941 942 929 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 957 958 945 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
A characteristic of ageing muscle is fibre atrophy and loss of myonuclei [4, 5]. In particular, the regression in myonuclear content seems to be a key event in the process of age-related muscle atrophy. Our data confirmed that ageing leads to a reduction in global myonuclear density and to a poor fibre distribution profile (Fig. 8a, b). Furthermore, ageing results in a reduction of TLA muscle oxidative capabilities (Table 1), down-regulation of PPARbeta expression and transcriptional activity (Fig. 7). As we have demonstrated that PPARbeta pathway activation promotes both oxidative phenotype [10, 18] and myonuclear accretion (Figs. 1 and 2), it is tempting to speculate that PPARbeta down-regulation observed in muscle from aged animals is directly involved in the age-related reduction of both myonuclear density and oxidative phenotype in TLA. The findings showing that PPARbeta over-expression or pharmacological activation (Fig. 8a, b and Table 1) counteract, at least in part, the effects of ageing on these parameters suggest that PPARbeta activation could exert preventive or curative effects on both age-related muscle atrophy and reduction of oxidative phenotype.
###end p 69
###begin p 70
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 587 588 584 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 590 592 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 594 596 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">42</xref>
The effect of such import of new genetic material on the functional and metabolic abilities of muscle cells of treated animals remains to be determined. However, it may represent the basis for the rapid muscle plasticity and adaptation to aerobic exercise, possibly allowing a reprogramming of muscle cells toward a more oxidative phenotype, through an increased coding efficiency for contractile proteins and genes involved in fatty acid oxidation and mitochondrial biogenesis [39]. This hypothesis could explain the role of PPARbeta induction after various types of physical training [9, 18, 42]. Finally, our data indicate that, in addition to its beneficial effects on metabolism, PPARbeta agonists may represent a therapeutic approach for the treatment of age-related muscle atrophy.
###end p 70
###begin p 71
GW0742 was a generous gift from T.M. Willson (GlaxoSmithKline). The CREB antibody was a gift of M. Montminy. We thank E. Lendoye, M. Aupetit, M. Radjkhumar, F. Millot, J. Paput, G. Manfroni and G. Visciano for technical assistance. We thank Dr. Kay-Dietrich Wagner for critical reading of the manuscript. This work was supported by a grant to PG from the Agence Nationale de la Recherche (ANR-05-PCOD-012). NW has a fellowship from the Fondation de France. The authors have no conflicting financial interest.
###end p 71
###begin p 72
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 72
###begin title 73
References
###end title 73
###begin article-title 74
###xml 62 65 <span type="species:ncbi:10116">rat</span>
Time course of changes in markers of myogenesis in overloaded rat skeletal muscles
###end article-title 74
###begin article-title 75
Plasticity of myonuclear number in hypertrophied and atrophied mammalian skeletal muscle fibers
###end article-title 75
###begin article-title 76
Signaling pathways in skeletal muscle remodeling
###end article-title 76
###begin article-title 77
###xml 118 124 <span type="species:ncbi:10090">murine</span>
Evidence that satellite cell decrement contributes to preferential decline in nuclear number from large fibres during murine age-related muscle atrophy
###end article-title 77
###begin article-title 78
###xml 96 100 <span type="species:ncbi:10090">mice</span>
Distribution of myonuclei and microtubules in live muscle fibers of young, middle-aged, and old mice
###end article-title 78
###begin article-title 79
Molecular basis of skeletal muscle regeneration
###end article-title 79
###begin article-title 80
###xml 21 26 <span type="species:ncbi:9606">human</span>
Three members of the human pyruvate dehydrogenase kinase gene family are direct targets of the peroxisome proliferator-activated receptor beta/delta
###end article-title 80
###begin article-title 81
A calcineurin- and NFAT-dependent pathway regulates Myf5 gene expression in skeletal muscle reserve cells
###end article-title 81
###begin article-title 82
###xml 109 117 <span type="species:ncbi:9606">patients</span>
Low-intensity exercise increases skeletal muscle protein expression of PPARdelta and UCP3 in type 2 diabetic patients
###end article-title 82
###begin article-title 83
###xml 119 124 <span type="species:ncbi:10090">mouse</span>
Pharmacological activation of PPAR{beta} promotes rapid and calcineurin-dependent fiber remodeling and angiogenesis in mouse skeletal muscle
###end article-title 83
###begin article-title 84
Identification of skeletal muscle precursor cells in vivo by use of MyoD1 and myogenin probes
###end article-title 84
###begin article-title 85
Aging-sensitive cellular and molecular mechanisms associated with skeletal muscle hypertrophy
###end article-title 85
###begin article-title 86
Control of muscle fibre size: a crucial factor in ageing
###end article-title 86
###begin article-title 87
###xml 83 86 <span type="species:ncbi:10116">rat</span>
Localization of MyoD, myogenin and cell cycle regulatory factors in hypertrophying rat skeletal muscles
###end article-title 87
###begin article-title 88
###xml 57 61 <span type="species:ncbi:10090">mice</span>
Activation of PPARdelta alters lipid metabolism in db/db mice
###end article-title 88
###begin article-title 89
Resident stem cells are not required for exercise-induced fiber-type switching and angiogenesis but are necessary for activity-dependent muscle growth
###end article-title 89
###begin article-title 90
Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes
###end article-title 90
###begin article-title 91
Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability
###end article-title 91
###begin article-title 92
Satellite cell of skeletal muscle fibers
###end article-title 92
###begin article-title 93
###xml 29 34 <span type="species:ncbi:10090">mouse</span>
Gene targeting restricted to mouse striated muscle lineage
###end article-title 93
###begin article-title 94
A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport
###end article-title 94
###begin article-title 95
Control of Myf5 activation in adult skeletal myonuclei requires ERK signalling
###end article-title 95
###begin article-title 96
Peroxisome proliferator-activated receptor delta (PPARdelta) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis
###end article-title 96
###begin article-title 97
Satellite cell proliferation and the expression of myogenin and desmin in regenerating skeletal muscle: evidence for two different populations of satellite cells
###end article-title 97
###begin article-title 98
###xml 80 86 <span type="species:ncbi:10090">murine</span>
Fusion between myogenic cells in vivo: an ultrastructural study in regenerating murine skeletal muscle
###end article-title 98
###begin article-title 99
###xml 26 32 <span type="species:ncbi:10090">murine</span>
Elucidation of aspects of murine skeletal muscle regeneration using local and whole body irradiation
###end article-title 99
###begin article-title 100
Fusion between a myogenic cell in the satellite cell position and undamaged adult myofibre segments
###end article-title 100
###begin article-title 101
Fusion of myogenic cells to the newly sealed region of damaged myofibres in skeletal muscle regeneration
###end article-title 101
###begin article-title 102
###xml 72 75 <span type="species:ncbi:10116">rat</span>
Satellite cell activity is required for hypertrophy of overloaded adult rat muscle
###end article-title 102
###begin article-title 103
###xml 73 76 <span type="species:ncbi:10116">rat</span>
Modulation of myonuclear number in functionally overloaded and exercised rat plantaris fibers
###end article-title 103
###begin article-title 104
The molecular regulation of myogenesis
###end article-title 104
###begin article-title 105
Response of satellite cells and muscle fibers to long-term compensatory hypertrophy
###end article-title 105
###begin article-title 106
Satellite cell behavior during skeletal muscle growth and regeneration
###end article-title 106
###begin article-title 107
Vasopressin-dependent myogenic cell differentiation is mediated by both Ca2+/calmodulin-dependent kinase and calcineurin pathways
###end article-title 107
###begin article-title 108
###xml 79 82 <span type="species:ncbi:10116">rat</span>
Exercise-enhanced satellite cell proliferation and new myonuclear accretion in rat skeletal muscle
###end article-title 108
###begin article-title 109
Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist
###end article-title 109
###begin article-title 110
DNA synthesis and myogenesis
###end article-title 110
###begin article-title 111
Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)-synthesis and biological activity
###end article-title 111
###begin article-title 112
###xml 79 82 <span type="species:ncbi:10116">rat</span>
Cytoplasm-to-myonucleus ratios and succinate dehydrogenase activities in adult rat slow and fast muscle fibers
###end article-title 112
###begin article-title 113
Cellular and molecular signatures of muscle regeneration: current concepts and controversies in adult myogenesis
###end article-title 113
###begin article-title 114
Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity
###end article-title 114
###begin article-title 115
###xml 148 153 <span type="species:ncbi:9606">human</span>
Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) alpha and delta and PPAR coactivator 1alpha in human skeletal muscle, but not lipid regulatory genes
###end article-title 115
###begin article-title 116
Development and postnatal regulation of adult myoblasts
###end article-title 116
###begin article-title 117
Kinetics of myoblast proliferation show that resident satellite cells are competent to fully regenerate skeletal muscle fibers
###end article-title 117
###begin article-title 118
###xml 61 64 <span type="species:ncbi:10116">rat</span>
Effects of inactivity on fiber size and myonuclear number in rat soleus muscle
###end article-title 118

